TCGA
Breast cancer dataset (Nature 2012, 825 patients)
SUBTYPE | SUBTYPE2 | SUBTYPE3 | SAMPLE_ID | PATIENT_ID | Gender | AGE | ER Status | PR Status | HER2 Final Status | Tumor | Tumor--T1 Coded | Node | Node-Coded | Metastasis | Metastasis-Coded | AJCC Stage | Converted Stage | Survival Data Form | OS_STATUS | OS_MONTHS | PAM50 Subtype | SigClust Unsupervised mRNA | SigClust Intrinsic mRNA | miRNA Clusters | methylation Clusters | RPPA Clusters | CN Clusters | Integrated Clusters (with PAM50) | Integrated Clusters (no exp) | Integrated Clusters (unsup exp) | CANCER_TYPE | CANCER_TYPE_DETAILED | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | TNBC | TNBC | TNBC | TCGA-A2-A0T2-01 | TCGA-A2-A0T2-01 | FEMALE | 66.0 | Negative | Negative | Negative | T3 | T_Other | N3 | Positive | M1 | Positive | Stage IV | No_Conversion | followup | DECEASED | 7.89 | Basal-like | 0.0 | -13.0 | 3.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
1 | TNBC | TNBC | TNBC | TCGA-A2-A04P-01 | TCGA-A2-A04P-01 | FEMALE | 36.0 | Negative | Negative | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | DECEASED | 17.97 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
2 | TNBC | TNBC | TNBC | TCGA-A1-A0SK-01 | TCGA-A1-A0SK-01 | FEMALE | 54.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | DECEASED | 31.77 | Basal-like | -6.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
3 | TNBC | TNBC | TNBC | TCGA-A2-A0CM-01 | TCGA-A2-A0CM-01 | FEMALE | 40.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | DECEASED | 24.77 | Basal-like | -12.0 | -13.0 | 4.0 | 4.0 | Basal | 4.0 | 2.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
4 | TNBC | TNBC | TNBC | TCGA-AR-A1AR-01 | TCGA-AR-A1AR-01 | FEMALE | 50.0 | Negative | Negative | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | DECEASED | 17.18 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
5 | TNBC | TNBC | TNBC | TCGA-B6-A0WX-01 | TCGA-B6-A0WX-01 | FEMALE | 40.0 | Negative | Negative | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | DECEASED | 21.45 | Basal-like | 0.0 | -13.0 | 4.0 | 5.0 | X | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
6 | NaN | NaN | NaN | TCGA-BH-A1F0-01 | TCGA-BH-A1F0-01 | FEMALE | 80.0 | Negative | Indeterminate | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 25.79 | Basal-like | -12.0 | -13.0 | 6.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
7 | NaN | NaN | NaN | TCGA-B6-A0I6-01 | TCGA-B6-A0I6-01 | FEMALE | 49.0 | Negative | Negative | Not Available | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | DECEASED | 32.76 | Basal-like | 0.0 | -13.0 | 4.0 | 5.0 | Basal | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
8 | TNBC | TNBC | TNBC | TCGA-BH-A18V-01 | TCGA-BH-A18V-01 | FEMALE | 48.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | DECEASED | 51.09 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
9 | TNBC | TNBC | TNBC | TCGA-BH-A18Q-01 | TCGA-BH-A18Q-01 | FEMALE | 56.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | DECEASED | 55.59 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
10 | ER+ | ER+ | ER+ | TCGA-BH-A18K-01 | TCGA-BH-A18K-01 | FEMALE | 46.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | DECEASED | 90.75 | Basal-like | -12.0 | -13.0 | 5.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
11 | ER+ | ER+ | ER+ | TCGA-BH-A0HL-01 | TCGA-BH-A0HL-01 | FEMALE | 56.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 2.37 | Basal-like | 0.0 | -13.0 | 4.0 | 3.0 | LumA/B | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
12 | TNBC | TNBC | TNBC | TCGA-BH-A0E0-01 | TCGA-BH-A0E0-01 | FEMALE | 38.0 | Negative | Negative | Negative | T3 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 4.37 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
13 | TNBC | TNBC | TNBC | TCGA-BH-A0RX-01 | TCGA-BH-A0RX-01 | FEMALE | 59.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 5.59 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | ReacII | 4.0 | 2.0 | 3.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
14 | NaN | NaN | NaN | TCGA-A7-A13D-01 | TCGA-A7-A13D-01 | FEMALE | 46.0 | Negative | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 8.77 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | ReacII | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
15 | TNBC | TNBC | TNBC | TCGA-BH-A0E6-01 | TCGA-BH-A0E6-01 | FEMALE | 69.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 9.59 | Basal-like | 0.0 | -13.0 | 4.0 | 1.0 | ReacI | 1.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
16 | TNBC | TNBC | TNBC | TCGA-AO-A0J4-01 | TCGA-AO-A0J4-01 | FEMALE | 41.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 9.66 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
17 | TNBC | TNBC | TNBC | TCGA-A7-A0CE-01 | TCGA-A7-A0CE-01 | FEMALE | 57.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 10.15 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
18 | ER+ | ER+ | ER+ | TCGA-A7-A13E-01 | TCGA-A7-A13E-01 | FEMALE | 62.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 10.71 | Basal-like | -12.0 | -13.0 | 5.0 | 4.0 | Basal | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
19 | TNBC | TNBC | TNBC | TCGA-A7-A0DA-01 | TCGA-A7-A0DA-01 | FEMALE | 62.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 12.25 | Basal-like | 0.0 | -13.0 | 4.0 | 5.0 | X | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
20 | TNBC | TNBC | TNBC | TCGA-D8-A142-01 | TCGA-D8-A142-01 | FEMALE | 74.0 | Negative | Negative | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 13.96 | Basal-like | 0.0 | -13.0 | 3.0 | 5.0 | X | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
21 | TNBC | TNBC | TNBC | TCGA-D8-A143-01 | TCGA-D8-A143-01 | FEMALE | 51.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 14.16 | Basal-like | 0.0 | -13.0 | NaN | 5.0 | Basal | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
22 | TNBC | TNBC | TNBC | TCGA-AQ-A04J-01 | TCGA-AQ-A04J-01 | FEMALE | 45.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 16.39 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
23 | ER+ | ER+ | ER+ | TCGA-BH-A0HN-01 | TCGA-BH-A0HN-01 | FEMALE | 67.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 16.95 | Basal-like | 0.0 | -13.0 | 6.0 | 2.0 | ReacI | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
24 | TNBC | TNBC | TNBC | TCGA-A2-A0T0-01 | TCGA-A2-A0T0-01 | FEMALE | 59.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 17.51 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
25 | TNBC | TNBC | TNBC | TCGA-A2-A0YE-01 | TCGA-A2-A0YE-01 | FEMALE | 48.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 18.17 | Basal-like | -12.0 | -13.0 | NaN | 5.0 | X | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
26 | ER+ | ER+ | ER+ | TCGA-A2-A0YJ-01 | TCGA-A2-A0YJ-01 | FEMALE | 39.0 | Positive | Negative | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 18.56 | Basal-like | -12.0 | -13.0 | NaN | 5.0 | Basal | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
27 | TNBC | TNBC | TNBC | TCGA-A2-A0D0-01 | TCGA-A2-A0D0-01 | FEMALE | 60.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 21.13 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
28 | TNBC | TNBC | TNBC | TCGA-A2-A04U-01 | TCGA-A2-A04U-01 | FEMALE | 47.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 22.01 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
29 | TNBC | TNBC | TNBC | TCGA-AO-A0J6-01 | TCGA-AO-A0J6-01 | FEMALE | 61.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 25.46 | Basal-like | -12.0 | -13.0 | 2.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
30 | TNBC | TNBC | TNBC | TCGA-A2-A0YM-01 | TCGA-A2-A0YM-01 | FEMALE | 67.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 31.67 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
31 | TNBC | TNBC | TNBC | TCGA-A2-A0D2-01 | TCGA-A2-A0D2-01 | FEMALE | 45.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIA | followup | LIVING | 33.74 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
32 | TNBC | TNBC | TNBC | TCGA-BH-A0B3-01 | TCGA-BH-A0B3-01 | FEMALE | 53.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 39.52 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
33 | TNBC | TNBC | TNBC | TCGA-A2-A04Q-01 | TCGA-A2-A04Q-01 | FEMALE | 48.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 41.89 | Basal-like | -12.0 | -13.0 | 4.0 | 1.0 | ReacII | 3.0 | 3.0 | 1.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
34 | TNBC | TNBC | TNBC | TCGA-A2-A0SX-01 | TCGA-A2-A0SX-01 | FEMALE | 48.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 42.32 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
35 | TNBC | TNBC | TNBC | TCGA-AO-A0JL-01 | TCGA-AO-A0JL-01 | FEMALE | 59.0 | Negative | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 43.34 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
36 | TNBC | TNBC | TNBC | TCGA-AO-A12F-01 | TCGA-AO-A12F-01 | FEMALE | 36.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 48.33 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
37 | TNBC | TNBC | TNBC | TCGA-BH-A0B9-01 | TCGA-BH-A0B9-01 | FEMALE | 44.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 51.65 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
38 | TNBC | TNBC | TNBC | TCGA-A2-A04T-01 | TCGA-A2-A04T-01 | FEMALE | 62.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 73.79 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
39 | TNBC | TNBC | TNBC | TCGA-B6-A0RT-01 | TCGA-B6-A0RT-01 | FEMALE | 39.0 | Negative | Negative | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 89.40 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | ReacII | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
40 | TNBC | TNBC | TNBC | TCGA-AO-A128-01 | TCGA-AO-A128-01 | FEMALE | 61.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 94.52 | Basal-like | 0.0 | -13.0 | 6.0 | 5.0 | Basal | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
41 | TNBC | TNBC | TNBC | TCGA-AO-A129-01 | TCGA-AO-A129-01 | FEMALE | 29.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 96.04 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
42 | TNBC | TNBC | TNBC | TCGA-AO-A124-01 | TCGA-AO-A124-01 | FEMALE | 38.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 102.47 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
43 | TNBC | TNBC | TNBC | TCGA-B6-A0RU-01 | TCGA-B6-A0RU-01 | FEMALE | 49.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 131.12 | Basal-like | -11.0 | -13.0 | 6.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
44 | TNBC | TNBC | TNBC | TCGA-B6-A0IQ-01 | TCGA-B6-A0IQ-01 | FEMALE | 40.0 | Negative | Negative | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 140.75 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
45 | NaN | NaN | NaN | TCGA-B6-A0I2-01 | TCGA-B6-A0I2-01 | FEMALE | 45.0 | Performed but Not Available | Performed but Not Available | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 143.25 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | ReacII | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
46 | ER+ | ER+ | ER+ | TCGA-B6-A0IJ-01 | TCGA-B6-A0IJ-01 | FEMALE | 42.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 176.86 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
47 | NaN | NaN | NaN | TCGA-B6-A0X1-01 | TCGA-B6-A0X1-01 | FEMALE | 48.0 | Negative | Negative | Not Available | T2 | T_Other | N2 | Positive | M1 | Positive | Stage IV | No_Conversion | followup | LIVING | 186.32 | Basal-like | -12.0 | -13.0 | NaN | 5.0 | Basal | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
48 | TNBC | TNBC | TNBC | TCGA-B6-A0RE-01 | TCGA-B6-A0RE-01 | FEMALE | 61.0 | Negative | Negative | Negative | TX | NaN | N0 | Negative | M0 | Negative | NaN | No_Conversion | followup | LIVING | 211.39 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
49 | TNBC | TNBC | TNBC | TCGA-A2-A0ST-01 | TCGA-A2-A0ST-01 | FEMALE | 62.0 | Negative | Negative | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 53.98 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
50 | ER+ | ER+ | ER+ | TCGA-AR-A0TP-01 | TCGA-AR-A0TP-01 | FEMALE | 43.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 78.59 | Basal-like | -11.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
51 | TNBC | TNBC | TNBC | TCGA-A1-A0SO-01 | TCGA-A1-A0SO-01 | FEMALE | 67.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 27.99 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
52 | TNBC | TNBC | TNBC | TCGA-A8-A07C-01 | TCGA-A8-A07C-01 | FEMALE | 57.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.06 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
53 | TNBC | TNBC | TNBC | TCGA-A8-A07O-01 | TCGA-A8-A07O-01 | FEMALE | 51.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 9.99 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
54 | NaN | NaN | NaN | TCGA-A8-A07R-01 | TCGA-A8-A07R-01 | FEMALE | 80.0 | Negative | Negative | Equivocal | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 8.97 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
55 | NaN | NaN | NaN | TCGA-A8-A07U-01 | TCGA-A8-A07U-01 | FEMALE | 66.0 | Negative | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 9.96 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
56 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A08H-01 | TCGA-A8-A08H-01 | FEMALE | 66.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Basal-like | -8.0 | -5.0 | 4.0 | 1.0 | ReacI | 1.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
57 | TNBC | TNBC | TNBC | TCGA-A8-A08R-01 | TCGA-A8-A08R-01 | FEMALE | 52.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.99 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
58 | TNBC | TNBC | TNBC | TCGA-AN-A04D-01 | TCGA-AN-A04D-01 | FEMALE | 58.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 1.71 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
59 | TNBC | TNBC | TNBC | TCGA-AN-A0AL-01 | TCGA-AN-A0AL-01 | FEMALE | 41.0 | Negative | Negative | Negative | T4 | T_Other | N0 | Negative | M0 | Negative | Stage IIIB | No_Conversion | enrollment | LIVING | 6.47 | Basal-like | 0.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
60 | TNBC | TNBC | TNBC | TCGA-AN-A0AR-01 | TCGA-AN-A0AR-01 | FEMALE | 55.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.30 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
61 | TNBC | TNBC | TNBC | TCGA-AN-A0AT-01 | TCGA-AN-A0AT-01 | FEMALE | 62.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.33 | Basal-like | -12.0 | -13.0 | NaN | 5.0 | Basal | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
62 | ER+ | ER+ | ER+ | TCGA-AN-A0FJ-01 | TCGA-AN-A0FJ-01 | FEMALE | 59.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IV | No_Conversion | enrollment | LIVING | 7.92 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
63 | TNBC | TNBC | TNBC | TCGA-AN-A0FL-01 | TCGA-AN-A0FL-01 | FEMALE | 62.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 7.56 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
64 | TNBC | TNBC | TNBC | TCGA-AN-A0FX-01 | TCGA-AN-A0FX-01 | FEMALE | 52.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.33 | Basal-like | -11.0 | -13.0 | 4.0 | 4.0 | ReacII | 1.0 | 2.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
65 | TNBC | TNBC | TNBC | TCGA-AN-A0G0-01 | TCGA-AN-A0G0-01 | FEMALE | 56.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.53 | Basal-like | 0.0 | -13.0 | 3.0 | 5.0 | Basal | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
66 | TNBC | TNBC | TNBC | TCGA-AN-A0XU-01 | TCGA-AN-A0XU-01 | FEMALE | 54.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.33 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
67 | TNBC | TNBC | TNBC | TCGA-AR-A0TS-01 | TCGA-AR-A0TS-01 | FEMALE | 46.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 37.39 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 4.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
68 | TNBC | TNBC | TNBC | TCGA-AR-A0TU-01 | TCGA-AR-A0TU-01 | FEMALE | 35.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 11.83 | Basal-like | -12.0 | -13.0 | NaN | 5.0 | Basal | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
69 | TNBC | TNBC | TNBC | TCGA-AR-A0U0-01 | TCGA-AR-A0U0-01 | FEMALE | 73.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 0.26 | Basal-like | -12.0 | -13.0 | NaN | 1.0 | Basal | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
70 | TNBC | TNBC | TNBC | TCGA-AR-A0U1-01 | TCGA-AR-A0U1-01 | FEMALE | 36.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 6.08 | Basal-like | 0.0 | -13.0 | 6.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
71 | TNBC | TNBC | TNBC | TCGA-AR-A0U4-01 | TCGA-AR-A0U4-01 | FEMALE | 54.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 53.46 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | ReacII | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
72 | ER+ | ER+ | ER+ | TCGA-AR-A1AH-01 | TCGA-AR-A1AH-01 | FEMALE | 51.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 75.50 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
73 | TNBC | TNBC | TNBC | TCGA-AR-A1AI-01 | TCGA-AR-A1AI-01 | FEMALE | 47.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 61.80 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
74 | ER+ | ER+ | ER+ | TCGA-AR-A1AJ-01 | TCGA-AR-A1AJ-01 | FEMALE | 83.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 52.70 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | ReacI | 3.0 | 2.0 | 1.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
75 | TNBC | TNBC | TNBC | TCGA-AR-A1AQ-01 | TCGA-AR-A1AQ-01 | FEMALE | 49.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 43.01 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
76 | TNBC | TNBC | TNBC | TCGA-AR-A1AY-01 | TCGA-AR-A1AY-01 | FEMALE | 65.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 20.17 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
77 | TNBC | TNBC | TNBC | TCGA-BH-A0AV-01 | TCGA-BH-A0AV-01 | FEMALE | 52.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 38.77 | Basal-like | 0.0 | -13.0 | 4.0 | 5.0 | ReacII | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
78 | TNBC | TNBC | TNBC | TCGA-BH-A0BG-01 | TCGA-BH-A0BG-01 | FEMALE | 73.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 24.84 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
79 | TNBC | TNBC | TNBC | TCGA-BH-A0BL-01 | TCGA-BH-A0BL-01 | FEMALE | 35.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 43.99 | Basal-like | -12.0 | -13.0 | 4.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
80 | TNBC | TNBC | TNBC | TCGA-BH-A0BW-01 | TCGA-BH-A0BW-01 | FEMALE | 71.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 11.66 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
81 | ER+ | ER+ | ER+ | TCGA-BH-A0DL-01 | TCGA-BH-A0DL-01 | FEMALE | 64.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 48.20 | Basal-like | 0.0 | -13.0 | 4.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
82 | TNBC | TNBC | TNBC | TCGA-BH-A0WA-01 | TCGA-BH-A0WA-01 | FEMALE | 82.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 12.22 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
83 | TNBC | TNBC | TNBC | TCGA-BH-A18G-01 | TCGA-BH-A18G-01 | FEMALE | 81.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage X | No_Conversion | enrollment | LIVING | 2.00 | Basal-like | 0.0 | -13.0 | 4.0 | 4.0 | Basal | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
84 | NaN | NaN | NaN | TCGA-C8-A12K-01 | TCGA-C8-A12K-01 | FEMALE | 80.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 0.00 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
85 | TNBC | TNBC | TNBC | TCGA-C8-A12V-01 | TCGA-C8-A12V-01 | FEMALE | 55.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
86 | TNBC | TNBC | TNBC | TCGA-C8-A131-01 | TCGA-C8-A131-01 | FEMALE | 82.0 | Negative | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 0.00 | Basal-like | 0.0 | -13.0 | 5.0 | 1.0 | ReacII | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
87 | TNBC | TNBC | TNBC | TCGA-C8-A134-01 | TCGA-C8-A134-01 | FEMALE | 52.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.00 | Basal-like | -12.0 | -13.0 | 6.0 | 4.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
88 | TNBC | TNBC | TNBC | TCGA-D8-A147-01 | TCGA-D8-A147-01 | FEMALE | 45.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage X | Stage IIA | enrollment | LIVING | 0.07 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
89 | TNBC | TNBC | TNBC | TCGA-E2-A14N-01 | TCGA-E2-A14N-01 | FEMALE | 37.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 44.35 | Basal-like | -12.0 | -13.0 | 6.0 | 5.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
90 | TNBC | TNBC | TNBC | TCGA-E2-A14R-01 | TCGA-E2-A14R-01 | FEMALE | 62.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 27.76 | Basal-like | -12.0 | -13.0 | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
91 | TNBC | TNBC | TNBC | TCGA-E2-A14X-01 | TCGA-E2-A14X-01 | FEMALE | 55.0 | Negative | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 22.74 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | ReacII | 4.0 | 2.0 | 3.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
92 | HER2+ | ER+ | ER+/HER2+ | TCGA-E2-A14Y-01 | TCGA-E2-A14Y-01 | FEMALE | 35.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 22.60 | Basal-like | 0.0 | -13.0 | 5.0 | 2.0 | ReacII | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
93 | TNBC | TNBC | TNBC | TCGA-E2-A150-01 | TCGA-E2-A150-01 | FEMALE | 48.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.42 | Basal-like | -12.0 | -13.0 | 3.0 | 5.0 | X | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
94 | TNBC | TNBC | TNBC | TCGA-E2-A158-01 | TCGA-E2-A158-01 | FEMALE | 43.0 | Negative | Negative | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 14.78 | Basal-like | 0.0 | -13.0 | 5.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
95 | TNBC | TNBC | TNBC | TCGA-E2-A159-01 | TCGA-E2-A159-01 | FEMALE | 50.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 16.92 | Basal-like | -10.0 | -13.0 | 3.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
96 | TNBC | TNBC | TNBC | TCGA-E2-A1AZ-01 | TCGA-E2-A1AZ-01 | FEMALE | 63.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 64.53 | Basal-like | -12.0 | -13.0 | NaN | 5.0 | Basal | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
97 | ER+ | ER+ | ER+ | TCGA-E2-A1B5-01 | TCGA-E2-A1B5-01 | FEMALE | 46.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 25.43 | Basal-like | -12.0 | -13.0 | 6.0 | 1.0 | ReacI | 3.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
98 | ER+ | ER+ | ER+ | TCGA-A8-A08L-01 | TCGA-A8-A08L-01 | FEMALE | 89.0 | Positive | Negative | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | DECEASED | 9.99 | HER2-enriched | -6.0 | -2.0 | 1.0 | 4.0 | X | 1.0 | 1.0 | 5.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
99 | ER+ | ER+ | ER+ | TCGA-BH-A1EV-01 | TCGA-BH-A1EV-01 | FEMALE | 45.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 11.99 | HER2-enriched | -5.0 | -1.0 | 7.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
100 | HER2+ | HER2+ | None | TCGA-B6-A0I9-01 | TCGA-B6-A0I9-01 | FEMALE | 62.0 | Indeterminate | Positive | Positive | T3 | T_Other | N0 | Negative | M1 | Positive | Stage IV | No_Conversion | followup | DECEASED | 12.12 | HER2-enriched | -5.0 | -2.0 | 4.0 | 4.0 | Her2 | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
101 | TNBC | TNBC | TNBC | TCGA-A8-A09X-01 | TCGA-A8-A09X-01 | FEMALE | 62.0 | Negative | Negative | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | DECEASED | 14.00 | HER2-enriched | -5.0 | -11.0 | 3.0 | 4.0 | Her2 | 3.0 | 1.0 | 2.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
102 | TNBC | TNBC | TNBC | TCGA-B6-A0IK-01 | TCGA-B6-A0IK-01 | FEMALE | 63.0 | Negative | Negative | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | No_Conversion | followup | DECEASED | 18.76 | HER2-enriched | -5.0 | -11.0 | 4.0 | 4.0 | ReacII | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
103 | ER+ | ER+ | ER+ | TCGA-BH-A18P-01 | TCGA-BH-A18P-01 | FEMALE | 60.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | DECEASED | 30.26 | HER2-enriched | -1.0 | -1.0 | 5.0 | 4.0 | X | 2.0 | 1.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
104 | ER+ | ER+ | ER+ | TCGA-A8-A08J-01 | TCGA-A8-A08J-01 | FEMALE | 52.0 | Positive | Negative | Negative | T4 | T_Other | N3 | Positive | M1 | Positive | Stage IV | Stage IV | enrollment | DECEASED | 37.03 | HER2-enriched | -5.0 | -2.0 | 4.0 | 4.0 | Her2 | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
105 | HER2+ | HER2+ | None | TCGA-BH-A18R-01 | TCGA-BH-A18R-01 | FEMALE | 50.0 | Indeterminate | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IB | No_Conversion | enrollment | DECEASED | 37.49 | HER2-enriched | 0.0 | -2.0 | 4.0 | 4.0 | Her2 | 3.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
106 | HER2+ | ER+ | ER+/HER2+ | TCGA-AR-A1AT-01 | TCGA-AR-A1AT-01 | FEMALE | 62.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | DECEASED | 41.79 | HER2-enriched | -5.0 | -11.0 | 4.0 | 1.0 | Her2 | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
107 | TNBC | TNBC | TNBC | TCGA-B6-A0RS-01 | TCGA-B6-A0RS-01 | FEMALE | 38.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | DECEASED | 100.60 | HER2-enriched | 0.0 | 0.0 | 4.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
108 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A0DZ-01 | TCGA-BH-A0DZ-01 | FEMALE | 43.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 16.26 | HER2-enriched | -3.0 | -2.0 | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
109 | HER2+ | HER2+ | ER-/HER2+ | TCGA-A2-A0T1-01 | TCGA-A2-A0T1-01 | FEMALE | 55.0 | Negative | Negative | Positive | T3 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 17.08 | HER2-enriched | -5.0 | -11.0 | 4.0 | 5.0 | Her2 | 4.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
110 | TNBC | TNBC | TNBC | TCGA-AO-A0J2-01 | TCGA-AO-A0J2-01 | FEMALE | 41.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 19.22 | HER2-enriched | -9.0 | -11.0 | 4.0 | 5.0 | Basal | 3.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
111 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A0AW-01 | TCGA-BH-A0AW-01 | FEMALE | 56.0 | Positive | Negative | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 20.44 | HER2-enriched | -5.0 | -11.0 | 5.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
112 | HER2+ | HER2+ | ER-/HER2+ | TCGA-BH-A0EE-01 | TCGA-BH-A0EE-01 | FEMALE | 68.0 | Negative | Negative | Positive | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 30.98 | HER2-enriched | -9.0 | -11.0 | 7.0 | 1.0 | Basal | 5.0 | 1.0 | 2.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
113 | HER2+ | HER2+ | ER-/HER2+ | TCGA-A2-A0D1-01 | TCGA-A2-A0D1-01 | FEMALE | 76.0 | Negative | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 34.53 | HER2-enriched | -6.0 | -2.0 | 1.0 | 3.0 | Basal | 1.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
114 | ER+ | ER+ | ER+ | TCGA-AO-A03N-01 | TCGA-AO-A03N-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 54.05 | HER2-enriched | -3.0 | -2.0 | 6.0 | 2.0 | Her2 | 3.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
115 | ER+ | ER+ | ER+ | TCGA-A2-A0CY-01 | TCGA-A2-A0CY-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 54.97 | HER2-enriched | -3.0 | 0.0 | 7.0 | 5.0 | LumA/B | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
116 | HER2+ | ER+ | ER+/HER2+ | TCGA-A2-A04X-01 | TCGA-A2-A04X-01 | FEMALE | 34.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 55.39 | HER2-enriched | -5.0 | -2.0 | 4.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
117 | HER2+ | ER+ | ER+/HER2+ | TCGA-A2-A0CX-01 | TCGA-A2-A0CX-01 | FEMALE | 52.0 | Positive | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 56.77 | HER2-enriched | -5.0 | -11.0 | NaN | 4.0 | Her2 | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
118 | HER2+ | HER2+ | ER-/HER2+ | TCGA-A2-A04W-01 | TCGA-A2-A04W-01 | FEMALE | 50.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 64.00 | HER2-enriched | -5.0 | -11.0 | 4.0 | 1.0 | Her2 | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
119 | HER2+ | HER2+ | ER-/HER2+ | TCGA-AO-A12D-01 | TCGA-AO-A12D-01 | FEMALE | 43.0 | Negative | Negative | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 64.00 | HER2-enriched | -10.0 | -11.0 | 3.0 | 5.0 | Her2 | 3.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
120 | ER+ | ER+ | ER+ | TCGA-A2-A0CL-01 | TCGA-A2-A0CL-01 | FEMALE | 37.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 64.49 | HER2-enriched | -5.0 | -2.0 | 4.0 | 1.0 | Basal | 3.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
121 | HER2+ | HER2+ | ER-/HER2+ | TCGA-AO-A0JE-01 | TCGA-AO-A0JE-01 | FEMALE | 53.0 | Negative | Negative | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 64.56 | HER2-enriched | -5.0 | -11.0 | 4.0 | 4.0 | Her2 | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
122 | HER2+ | HER2+ | ER-/HER2+ | TCGA-A2-A0EQ-01 | TCGA-A2-A0EQ-01 | FEMALE | 64.0 | Negative | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 79.71 | HER2-enriched | -5.0 | -2.0 | 5.0 | 4.0 | Basal | 4.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
123 | ER+ | ER+ | ER+ | TCGA-AO-A03L-01 | TCGA-AO-A03L-01 | FEMALE | 34.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 80.23 | HER2-enriched | -4.0 | -2.0 | 1.0 | 4.0 | Basal | 5.0 | 1.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
124 | HER2+ | ER+ | ER+/HER2+ | TCGA-B6-A0RH-01 | TCGA-B6-A0RH-01 | FEMALE | 51.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 188.85 | HER2-enriched | -5.0 | -1.0 | 6.0 | 2.0 | ReacII | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
125 | ER+ | ER+ | ER+ | TCGA-A8-A075-01 | TCGA-A8-A075-01 | FEMALE | 42.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 16.99 | HER2-enriched | -5.0 | -2.0 | 1.0 | 5.0 | X | 2.0 | 1.0 | 5.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
126 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A076-01 | TCGA-A8-A076-01 | FEMALE | 66.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 53.91 | HER2-enriched | -5.0 | -2.0 | 4.0 | 3.0 | Her2 | 4.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
127 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A07B-01 | TCGA-A8-A07B-01 | FEMALE | 69.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 32.99 | HER2-enriched | -3.0 | -1.0 | 2.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
128 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A07I-01 | TCGA-A8-A07I-01 | FEMALE | 69.0 | Positive | Negative | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 14.00 | HER2-enriched | -5.0 | -2.0 | 4.0 | 3.0 | Her2 | 3.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
129 | ER+ | ER+ | ER+ | TCGA-A8-A081-01 | TCGA-A8-A081-01 | FEMALE | 80.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | HER2-enriched | -5.0 | -2.0 | 3.0 | 4.0 | Her2 | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
130 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A08B-01 | TCGA-A8-A08B-01 | FEMALE | 52.0 | Positive | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 23.06 | HER2-enriched | -5.0 | -1.0 | 7.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
131 | HER2+ | HER2+ | ER-/HER2+ | TCGA-A8-A08X-01 | TCGA-A8-A08X-01 | FEMALE | 43.0 | Negative | Negative | Positive | T4 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 33.97 | HER2-enriched | -10.0 | -13.0 | 3.0 | 1.0 | Her2 | 3.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
132 | ER+ | ER+ | ER+ | TCGA-A8-A092-01 | TCGA-A8-A092-01 | FEMALE | 48.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 17.02 | HER2-enriched | -3.0 | -2.0 | 4.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
133 | ER+ | ER+ | ER+ | TCGA-A8-A094-01 | TCGA-A8-A094-01 | FEMALE | 75.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | HER2-enriched | -5.0 | -11.0 | 3.0 | 1.0 | Basal | 1.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
134 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A09G-01 | TCGA-A8-A09G-01 | FEMALE | 79.0 | Positive | Negative | Positive | T3 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 0.00 | HER2-enriched | -5.0 | -11.0 | 3.0 | 1.0 | Her2 | 2.0 | 1.0 | 3.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
135 | HER2+ | HER2+ | ER-/HER2+ | TCGA-A8-A0A7-01 | TCGA-A8-A0A7-01 | FEMALE | 57.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.99 | HER2-enriched | -5.0 | -2.0 | 4.0 | 1.0 | Her2 | 3.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
136 | HER2+ | HER2+ | ER-/HER2+ | TCGA-AN-A04C-01 | TCGA-AN-A04C-01 | FEMALE | 51.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 1.77 | HER2-enriched | -9.0 | -11.0 | 5.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
137 | HER2+ | HER2+ | ER-/HER2+ | TCGA-AN-A0FV-01 | TCGA-AN-A0FV-01 | FEMALE | 58.0 | Negative | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.33 | HER2-enriched | -5.0 | -11.0 | 4.0 | 2.0 | Her2 | 1.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
138 | HER2+ | ER+ | ER+/HER2+ | TCGA-AR-A0TX-01 | TCGA-AR-A0TX-01 | FEMALE | 64.0 | Positive | Positive | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 0.49 | HER2-enriched | -5.0 | -11.0 | 1.0 | 1.0 | ReacII | 1.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
139 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A0B7-01 | TCGA-BH-A0B7-01 | FEMALE | 42.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 56.94 | HER2-enriched | -8.0 | -11.0 | 3.0 | 5.0 | Her2 | 3.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
140 | ER+ | ER+ | ER+ | TCGA-BH-A0HY-01 | TCGA-BH-A0HY-01 | FEMALE | 60.0 | Positive | Negative | Not Available | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 28.49 | HER2-enriched | -5.0 | -1.0 | 4.0 | 3.0 | ReacII | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
141 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A12L-01 | TCGA-C8-A12L-01 | FEMALE | 67.0 | Negative | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | HER2-enriched | -9.0 | -11.0 | 4.0 | 4.0 | Her2 | 1.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
142 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A12P-01 | TCGA-C8-A12P-01 | FEMALE | 55.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 0.00 | HER2-enriched | -10.0 | -11.0 | 4.0 | 1.0 | Her2 | 3.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
143 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A12Q-01 | TCGA-C8-A12Q-01 | FEMALE | 78.0 | Negative | Negative | Positive | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | enrollment | LIVING | 0.00 | HER2-enriched | -5.0 | -11.0 | 4.0 | 2.0 | Her2 | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
144 | HER2+ | ER+ | ER+/HER2+ | TCGA-C8-A12T-01 | TCGA-C8-A12T-01 | FEMALE | 43.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | HER2-enriched | -1.0 | -2.0 | 4.0 | 4.0 | ReacII | 4.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
145 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A12Z-01 | TCGA-C8-A12Z-01 | FEMALE | 45.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 0.00 | HER2-enriched | -5.0 | -11.0 | 4.0 | 4.0 | Her2 | 2.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
146 | ER+ | ER+ | ER+ | TCGA-C8-A130-01 | TCGA-C8-A130-01 | FEMALE | 52.0 | Positive | Positive | Equivocal | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.00 | HER2-enriched | 0.0 | -2.0 | 4.0 | 2.0 | Her2 | 1.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
147 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A135-01 | TCGA-C8-A135-01 | FEMALE | 64.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 0.00 | HER2-enriched | -5.0 | -11.0 | 7.0 | 1.0 | Her2 | 1.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
148 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A137-01 | TCGA-C8-A137-01 | FEMALE | 34.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 0.10 | HER2-enriched | -5.0 | -11.0 | NaN | 4.0 | Her2 | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
149 | HER2+ | ER+ | ER+/HER2+ | TCGA-C8-A138-01 | TCGA-C8-A138-01 | FEMALE | 54.0 | Positive | Negative | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 0.23 | HER2-enriched | -5.0 | -2.0 | 1.0 | 2.0 | Basal | 2.0 | 1.0 | 3.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
150 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A1HF-01 | TCGA-C8-A1HF-01 | FEMALE | 48.0 | Negative | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | HER2-enriched | -5.0 | -11.0 | 6.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
151 | TNBC | TNBC | TNBC | TCGA-D8-A13Z-01 | TCGA-D8-A13Z-01 | FEMALE | 51.0 | Negative | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage X | Stage IIIA | enrollment | LIVING | 6.90 | HER2-enriched | -10.0 | -13.0 | 4.0 | 1.0 | Basal | 1.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
152 | HER2+ | HER2+ | ER-/HER2+ | TCGA-E2-A14P-01 | TCGA-E2-A14P-01 | FEMALE | 79.0 | Negative | Negative | Positive | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 16.00 | HER2-enriched | -5.0 | -11.0 | 4.0 | 1.0 | Her2 | 3.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
153 | HER2+ | ER+ | ER+/HER2+ | TCGA-E2-A14V-01 | TCGA-E2-A14V-01 | FEMALE | 53.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 24.58 | HER2-enriched | -5.0 | -1.0 | 4.0 | 4.0 | Her2 | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
154 | HER2+ | ER+ | ER+/HER2+ | TCGA-E2-A152-01 | TCGA-E2-A152-01 | FEMALE | 56.0 | Positive | Negative | Positive | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 19.32 | HER2-enriched | -5.0 | -1.0 | 5.0 | 1.0 | Her2 | 1.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
155 | HER2+ | HER2+ | ER-/HER2+ | TCGA-E2-A1B0-01 | TCGA-E2-A1B0-01 | FEMALE | 50.0 | Negative | Negative | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 41.76 | HER2-enriched | -10.0 | -13.0 | 4.0 | 5.0 | ReacI | 3.0 | 2.0 | 1.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
156 | ER+ | ER+ | ER+ | TCGA-A2-A0CU-01 | TCGA-A2-A0CU-01 | FEMALE | 73.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | DECEASED | 5.16 | Luminal A | -3.0 | 0.0 | 2.0 | 2.0 | LumA/B | 5.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
157 | ER+ | ER+ | ER+ | TCGA-AR-A0TR-01 | TCGA-AR-A0TR-01 | FEMALE | 68.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | No_Conversion | enrollment | DECEASED | 5.26 | Luminal A | -3.0 | -12.0 | 7.0 | 2.0 | LumA/B | 1.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
158 | TNBC | TNBC | TNBC | TCGA-BH-A18T-01 | TCGA-BH-A18T-01 | FEMALE | 70.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 7.36 | Luminal A | -3.0 | 0.0 | 2.0 | 5.0 | ReacII | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
159 | NaN | NaN | NaN | TCGA-B6-A0I8-01 | TCGA-B6-A0I8-01 | FEMALE | 46.0 | Not Performed | Not Performed | Not Available | T1 | T1 | N0 | Negative | M0 | Negative | NaN | No_Conversion | followup | DECEASED | 24.61 | Luminal A | -3.0 | 0.0 | 4.0 | 2.0 | Her2 | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
160 | ER+ | ER+ | ER+ | TCGA-B6-A0X4-01 | TCGA-B6-A0X4-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | DECEASED | 28.22 | Luminal A | -3.0 | -12.0 | 1.0 | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
161 | ER+ | ER+ | ER+ | TCGA-A8-A06U-01 | TCGA-A8-A06U-01 | FEMALE | 80.0 | Positive | Positive | Equivocal | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | DECEASED | 28.98 | Luminal A | -5.0 | -2.0 | 4.0 | 4.0 | LumA/B | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
162 | ER+ | ER+ | ER+ | TCGA-BH-A0EA-01 | TCGA-BH-A0EA-01 | FEMALE | 72.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 32.62 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
163 | ER+ | ER+ | ER+ | TCGA-BH-A18N-01 | TCGA-BH-A18N-01 | FEMALE | 88.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | enrollment | DECEASED | 37.72 | Luminal A | -3.0 | -12.0 | 6.0 | 2.0 | LumA | 3.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
164 | ER+ | ER+ | ER+ | TCGA-BH-A1EU-01 | TCGA-BH-A1EU-01 | FEMALE | 83.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | DECEASED | 42.25 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
165 | ER+ | ER+ | ER+ | TCGA-B6-A0X7-01 | TCGA-B6-A0X7-01 | FEMALE | 62.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | NaN | NaN | NaN | No_Conversion | enrollment | DECEASED | 58.84 | Luminal A | -3.0 | -5.0 | 3.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
166 | ER+ | ER+ | ER+ | TCGA-A2-A04V-01 | TCGA-A2-A04V-01 | FEMALE | 39.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 63.08 | Luminal A | -3.0 | 0.0 | 2.0 | 2.0 | LumA/B | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
167 | ER+ | ER+ | ER+ | TCGA-BH-A18S-01 | TCGA-BH-A18S-01 | FEMALE | 79.0 | Positive | Positive | Not Available | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | DECEASED | 66.01 | Luminal A | -3.0 | -12.0 | 7.0 | 2.0 | LumA/B | 5.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
168 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A18M-01 | TCGA-BH-A18M-01 | FEMALE | 39.0 | Positive | Positive | Positive | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIIA | enrollment | DECEASED | 72.51 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
169 | ER+ | ER+ | ER+ | TCGA-B6-A0RM-01 | TCGA-B6-A0RM-01 | FEMALE | 57.0 | Positive | Positive | Negative | TX | NaN | N0 | Negative | NaN | NaN | NaN | No_Conversion | followup | DECEASED | 77.96 | Luminal A | -3.0 | -10.0 | 2.0 | 2.0 | LumA | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
170 | ER+ | ER+ | ER+ | TCGA-BH-A1ET-01 | TCGA-BH-A1ET-01 | FEMALE | 55.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IIA | Stage I | enrollment | DECEASED | 82.79 | Luminal A | -7.0 | -12.0 | 6.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
171 | ER+ | ER+ | ER+ | TCGA-B6-A0IN-01 | TCGA-B6-A0IN-01 | FEMALE | 45.0 | Positive | Negative | Not Available | T1 | T1 | N0 | Negative | NaN | NaN | NaN | No_Conversion | followup | DECEASED | 84.54 | Luminal A | -3.0 | -2.0 | 1.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
172 | ER+ | ER+ | ER+ | TCGA-BH-A1EO-01 | TCGA-BH-A1EO-01 | FEMALE | 68.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 91.93 | Luminal A | -3.0 | -5.0 | 6.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
173 | ER+ | ER+ | ER+ | TCGA-B6-A0WS-01 | TCGA-B6-A0WS-01 | FEMALE | 58.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | NaN | Stage I | followup | DECEASED | 97.41 | Luminal A | -4.0 | 0.0 | 7.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
174 | ER+ | ER+ | ER+ | TCGA-B6-A0RP-01 | TCGA-B6-A0RP-01 | FEMALE | 73.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | No_Conversion | followup | DECEASED | 102.70 | Luminal A | -4.0 | -12.0 | 4.0 | 2.0 | LumA | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
175 | ER+ | ER+ | ER+ | TCGA-B6-A0IH-01 | TCGA-B6-A0IH-01 | FEMALE | 81.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | followup | DECEASED | 112.30 | Luminal A | -7.0 | -5.0 | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
176 | ER+ | ER+ | ER+ | TCGA-B6-A0WY-01 | TCGA-B6-A0WY-01 | FEMALE | 40.0 | Positive | Negative | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | DECEASED | 113.68 | Luminal A | -3.0 | -5.0 | 4.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
177 | ER+ | ER+ | ER+ | TCGA-BH-A1ES-01 | TCGA-BH-A1ES-01 | FEMALE | 35.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | DECEASED | 113.74 | Luminal A | -3.0 | -9.0 | 5.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
178 | ER+ | ER+ | ER+ | TCGA-B6-A0X0-01 | TCGA-B6-A0X0-01 | FEMALE | 54.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | DECEASED | 129.61 | Luminal A | -3.0 | -5.0 | 7.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
179 | ER+ | ER+ | ER+ | TCGA-B6-A0RQ-01 | TCGA-B6-A0RQ-01 | FEMALE | 68.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | DECEASED | 140.39 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 1.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
180 | ER+ | ER+ | ER+ | TCGA-B6-A0IG-01 | TCGA-B6-A0IG-01 | FEMALE | 50.0 | Positive | Positive | Not Available | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | DECEASED | 146.40 | Luminal A | 0.0 | -2.0 | 7.0 | 4.0 | Her2 | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
181 | ER+ | ER+ | ER+ | TCGA-BH-A0HO-01 | TCGA-BH-A0HO-01 | FEMALE | 48.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 2.50 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
182 | ER+ | ER+ | ER+ | TCGA-BH-A0DS-01 | TCGA-BH-A0DS-01 | FEMALE | 71.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 2.53 | Luminal A | -7.0 | -5.0 | 6.0 | 3.0 | LumA | 3.0 | 3.0 | 4.0 | 5.0 | Breast Cancer | Invasive Breast Carcinoma |
183 | ER+ | ER+ | ER+ | TCGA-BH-A0DQ-01 | TCGA-BH-A0DQ-01 | FEMALE | 42.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 3.22 | Luminal A | 0.0 | -5.0 | 6.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
184 | ER+ | ER+ | ER+ | TCGA-BH-A0HK-01 | TCGA-BH-A0HK-01 | FEMALE | 81.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 5.85 | Luminal A | 0.0 | 0.0 | 7.0 | 3.0 | LumA/B | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
185 | ER+ | ER+ | ER+ | TCGA-A7-A0CG-01 | TCGA-A7-A0CG-01 | FEMALE | 78.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 7.56 | Luminal A | -7.0 | -5.0 | 7.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
186 | NaN | NaN | NaN | TCGA-A7-A0CH-01 | TCGA-A7-A0CH-01 | FEMALE | 79.0 | Performed but Not Available | Performed but Not Available | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 7.62 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
187 | ER+ | ER+ | ER+ | TCGA-A7-A0DB-01 | TCGA-A7-A0DB-01 | FEMALE | 56.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 8.74 | Luminal A | -7.0 | -5.0 | 4.0 | 1.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
188 | ER+ | ER+ | ER+ | TCGA-A7-A0D9-01 | TCGA-A7-A0D9-01 | FEMALE | 37.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 8.94 | Luminal A | -3.0 | -3.0 | 5.0 | 2.0 | ReacII | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
189 | ER+ | ER+ | ER+ | TCGA-AO-A0J8-01 | TCGA-AO-A0J8-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 9.10 | Luminal A | -3.0 | -12.0 | 2.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
190 | ER+ | ER+ | ER+ | TCGA-BH-A0GZ-01 | TCGA-BH-A0GZ-01 | FEMALE | 62.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 10.78 | Luminal A | -3.0 | 0.0 | 2.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
191 | ER+ | ER+ | ER+ | TCGA-AO-A0JA-01 | TCGA-AO-A0JA-01 | FEMALE | 36.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 11.37 | Luminal A | -4.0 | -4.0 | 1.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
192 | ER+ | ER+ | ER+ | TCGA-AO-A0JF-01 | TCGA-AO-A0JF-01 | FEMALE | 68.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 11.63 | Luminal A | -7.0 | -5.0 | 7.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
193 | ER+ | ER+ | ER+ | TCGA-A7-A0CD-01 | TCGA-A7-A0CD-01 | FEMALE | 66.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 12.22 | Luminal A | -3.0 | -10.0 | 2.0 | 3.0 | LumA | 3.0 | 3.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
194 | ER+ | ER+ | ER+ | TCGA-D8-A145-01 | TCGA-D8-A145-01 | FEMALE | 80.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 13.47 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | ReacI | 1.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
195 | ER+ | ER+ | ER+ | TCGA-BH-A0HP-01 | TCGA-BH-A0HP-01 | FEMALE | 65.0 | Positive | Negative | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 13.60 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
196 | ER+ | ER+ | ER+ | TCGA-BH-A0DK-01 | TCGA-BH-A0DK-01 | FEMALE | 49.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 13.90 | Luminal A | -4.0 | -4.0 | 2.0 | 3.0 | LumA/B | 2.0 | 3.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
197 | ER+ | ER+ | ER+ | TCGA-BH-A0E2-01 | TCGA-BH-A0E2-01 | FEMALE | 49.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 14.29 | Luminal A | -3.0 | -8.0 | NaN | 4.0 | LumA/B | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
198 | ER+ | ER+ | ER+ | TCGA-A2-A0YI-01 | TCGA-A2-A0YI-01 | FEMALE | 62.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 14.49 | Luminal A | -4.0 | -12.0 | 4.0 | 1.0 | ReacI | 3.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
199 | ER+ | ER+ | ER+ | TCGA-A2-A0YL-01 | TCGA-A2-A0YL-01 | FEMALE | 48.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 14.62 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
200 | ER+ | ER+ | ER+ | TCGA-AO-A0JG-01 | TCGA-AO-A0JG-01 | FEMALE | 49.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 14.75 | Luminal A | -7.0 | -5.0 | 1.0 | 4.0 | LumA/B | 5.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
201 | ER+ | ER+ | ER+ | TCGA-A2-A0YF-01 | TCGA-A2-A0YF-01 | FEMALE | 67.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 15.41 | Luminal A | -3.0 | -12.0 | 1.0 | 2.0 | ReacII | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
202 | ER+ | ER+ | ER+ | TCGA-BH-A0DP-01 | TCGA-BH-A0DP-01 | FEMALE | 60.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 15.64 | Luminal A | -7.0 | -5.0 | 2.0 | 4.0 | ReacI | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
203 | ER+ | ER+ | ER+ | TCGA-BH-A0E1-01 | TCGA-BH-A0E1-01 | FEMALE | 52.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 15.67 | Luminal A | -3.0 | -12.0 | 6.0 | 2.0 | ReacII | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
204 | ER+ | ER+ | ER+ | TCGA-A2-A0T5-01 | TCGA-A2-A0T5-01 | FEMALE | 39.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIA | followup | LIVING | 17.45 | Luminal A | -3.0 | -5.0 | 6.0 | 2.0 | LumA | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
205 | ER+ | ER+ | ER+ | TCGA-A2-A0T6-01 | TCGA-A2-A0T6-01 | FEMALE | 50.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 18.89 | Luminal A | -7.0 | -5.0 | 2.0 | 4.0 | ReacI | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
206 | ER+ | ER+ | ER+ | TCGA-BH-A0HI-01 | TCGA-BH-A0HI-01 | FEMALE | 78.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 20.34 | Luminal A | -3.0 | -12.0 | 7.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
207 | ER+ | ER+ | ER+ | TCGA-A2-A0T7-01 | TCGA-A2-A0T7-01 | FEMALE | 51.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 20.73 | Luminal A | 0.0 | -3.0 | 4.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
208 | ER+ | ER+ | ER+ | TCGA-BH-A0BJ-01 | TCGA-BH-A0BJ-01 | FEMALE | 41.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 21.68 | Luminal A | -7.0 | -5.0 | 7.0 | 2.0 | ReacI | 3.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
209 | ER+ | ER+ | ER+ | TCGA-BH-A0H7-01 | TCGA-BH-A0H7-01 | FEMALE | 65.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 23.03 | Luminal A | -3.0 | -3.0 | 4.0 | 4.0 | ReacII | 3.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
210 | ER+ | ER+ | ER+ | TCGA-BH-A0HF-01 | TCGA-BH-A0HF-01 | FEMALE | 77.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 23.89 | Luminal A | -7.0 | -5.0 | 4.0 | 2.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
211 | ER+ | ER+ | ER+ | TCGA-BH-A0EB-01 | TCGA-BH-A0EB-01 | FEMALE | 69.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 24.48 | Luminal A | -4.0 | -12.0 | NaN | 1.0 | LumA | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
212 | ER+ | ER+ | ER+ | TCGA-BH-A0H6-01 | TCGA-BH-A0H6-01 | FEMALE | 82.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | No_Conversion | followup | LIVING | 24.54 | Luminal A | -3.0 | -5.0 | 2.0 | 2.0 | ReacI | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
213 | ER+ | ER+ | ER+ | TCGA-A2-A0YD-01 | TCGA-A2-A0YD-01 | FEMALE | 63.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 25.27 | Luminal A | -7.0 | -5.0 | 4.0 | 1.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
214 | ER+ | ER+ | ER+ | TCGA-BH-A0HB-01 | TCGA-BH-A0HB-01 | FEMALE | 55.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 26.48 | Luminal A | -3.0 | -8.0 | 4.0 | 1.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
215 | ER+ | ER+ | ER+ | TCGA-BH-A0HX-01 | TCGA-BH-A0HX-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 27.24 | Luminal A | -3.0 | -10.0 | 4.0 | 4.0 | LumA/B | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
216 | ER+ | ER+ | ER+ | TCGA-AO-A12H-01 | TCGA-AO-A12H-01 | FEMALE | 69.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 28.32 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | LumA/B | 1.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
217 | ER+ | ER+ | ER+ | TCGA-E2-A10E-01 | TCGA-E2-A10E-01 | FEMALE | 64.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 28.42 | Luminal A | -3.0 | -12.0 | 4.0 | 4.0 | LumA/B | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
218 | ER+ | ER+ | ER+ | TCGA-A2-A0D3-01 | TCGA-A2-A0D3-01 | FEMALE | 42.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 28.75 | Luminal A | -3.0 | -5.0 | 6.0 | 4.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
219 | ER+ | ER+ | ER+ | TCGA-E2-A10F-01 | TCGA-E2-A10F-01 | FEMALE | 47.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 28.85 | Luminal A | -4.0 | -5.0 | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
220 | ER+ | ER+ | ER+ | TCGA-AO-A03V-01 | TCGA-AO-A03V-01 | FEMALE | 41.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 29.11 | Luminal A | -3.0 | 0.0 | 7.0 | 2.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
221 | ER+ | ER+ | ER+ | TCGA-A2-A0EW-01 | TCGA-A2-A0EW-01 | FEMALE | 53.0 | Positive | Positive | Negative | T1 | T1 | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 29.70 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
222 | ER+ | ER+ | ER+ | TCGA-BH-A0GY-01 | TCGA-BH-A0GY-01 | FEMALE | 67.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 30.33 | Luminal A | -3.0 | -3.0 | 5.0 | 2.0 | ReacI | 3.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
223 | ER+ | ER+ | ER+ | TCGA-A2-A0EV-01 | TCGA-A2-A0EV-01 | FEMALE | 80.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 31.80 | Luminal A | -4.0 | 0.0 | 4.0 | 2.0 | ReacI | 3.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
224 | ER+ | ER+ | ER+ | TCGA-BH-A0BC-01 | TCGA-BH-A0BC-01 | FEMALE | 60.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 32.00 | Luminal A | -4.0 | -4.0 | 4.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
225 | ER+ | ER+ | ER+ | TCGA-A2-A0YC-01 | TCGA-A2-A0YC-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 32.49 | Luminal A | -3.0 | -12.0 | 4.0 | 4.0 | ReacII | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
226 | ER+ | ER+ | ER+ | TCGA-A2-A0EU-01 | TCGA-A2-A0EU-01 | FEMALE | 79.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 34.27 | Luminal A | -3.0 | -10.0 | 2.0 | 2.0 | ReacI | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
227 | ER+ | ER+ | ER+ | TCGA-A2-A0ET-01 | TCGA-A2-A0ET-01 | FEMALE | 58.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 35.02 | Luminal A | -3.0 | -10.0 | 1.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
228 | ER+ | ER+ | ER+ | TCGA-A2-A04Y-01 | TCGA-A2-A04Y-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 36.11 | Luminal A | -3.0 | -2.0 | 5.0 | 1.0 | LumA | 5.0 | 3.0 | 2.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
229 | ER+ | ER+ | ER+ | TCGA-BH-A0HQ-01 | TCGA-BH-A0HQ-01 | FEMALE | 56.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 36.83 | Luminal A | -3.0 | -5.0 | 2.0 | 4.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
230 | ER+ | ER+ | ER+ | TCGA-A2-A0ES-01 | TCGA-A2-A0ES-01 | FEMALE | 52.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 37.03 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacII | 4.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
231 | ER+ | ER+ | ER+ | TCGA-BH-A0BA-01 | TCGA-BH-A0BA-01 | FEMALE | 51.0 | Positive | Positive | Negative | T3 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 37.19 | Luminal A | 0.0 | -5.0 | 6.0 | 4.0 | ReacI | 3.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
232 | ER+ | ER+ | ER+ | TCGA-E2-A10B-01 | TCGA-E2-A10B-01 | FEMALE | 67.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 37.49 | Luminal A | -3.0 | -12.0 | 4.0 | 4.0 | LumA | 3.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
233 | ER+ | ER+ | ER+ | TCGA-BH-A0B1-01 | TCGA-BH-A0B1-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 37.72 | Luminal A | -3.0 | -3.0 | 6.0 | NaN | LumA/B | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
234 | ER+ | ER+ | ER+ | TCGA-BH-A0DH-01 | TCGA-BH-A0DH-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 37.98 | Luminal A | -3.0 | 0.0 | 1.0 | 3.0 | X | 2.0 | 3.0 | 5.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
235 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A0B4-01 | TCGA-BH-A0B4-01 | MALE | 65.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 39.13 | Luminal A | -3.0 | -3.0 | 6.0 | 4.0 | ReacII | 5.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
236 | ER+ | ER+ | ER+ | TCGA-BH-A0H9-01 | TCGA-BH-A0H9-01 | FEMALE | 69.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 40.97 | Luminal A | -3.0 | -3.0 | 6.0 | 5.0 | LumA/B | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
237 | ER+ | ER+ | ER+ | TCGA-AO-A0J9-01 | TCGA-AO-A0J9-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 41.23 | Luminal A | -3.0 | -2.0 | 2.0 | 4.0 | ReacI | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
238 | ER+ | ER+ | ER+ | TCGA-AO-A12G-01 | TCGA-AO-A12G-01 | FEMALE | 75.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 41.56 | Luminal A | 0.0 | -1.0 | 2.0 | 4.0 | LumA/B | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
239 | HER2+ | ER+ | ER+/HER2+ | TCGA-A2-A0SY-01 | TCGA-A2-A0SY-01 | FEMALE | 62.0 | Positive | Positive | Positive | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 44.26 | Luminal A | -7.0 | -5.0 | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
240 | ER+ | ER+ | ER+ | TCGA-BH-A0E7-01 | TCGA-BH-A0E7-01 | FEMALE | 79.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 44.75 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | LumA | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
241 | ER+ | ER+ | ER+ | TCGA-AO-A03M-01 | TCGA-AO-A03M-01 | FEMALE | 29.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 47.80 | Luminal A | -5.0 | -2.0 | 7.0 | 1.0 | ReacII | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
242 | ER+ | ER+ | ER+ | TCGA-BH-A0BV-01 | TCGA-BH-A0BV-01 | FEMALE | 78.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 49.91 | Luminal A | -4.0 | 0.0 | 7.0 | 4.0 | LumA/B | 5.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
243 | ER+ | ER+ | ER+ | TCGA-BH-A0B8-01 | TCGA-BH-A0B8-01 | FEMALE | 64.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IB | Stage I | followup | LIVING | 51.55 | Luminal A | -3.0 | -10.0 | 7.0 | 3.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
244 | ER+ | ER+ | ER+ | TCGA-A2-A0CZ-01 | TCGA-A2-A0CZ-01 | FEMALE | 46.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 53.06 | Luminal A | -7.0 | -5.0 | 2.0 | 1.0 | ReacII | 4.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
245 | ER+ | ER+ | ER+ | TCGA-A2-A0SU-01 | TCGA-A2-A0SU-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 54.57 | Luminal A | 0.0 | 0.0 | 2.0 | 2.0 | LumA/B | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
246 | ER+ | ER+ | ER+ | TCGA-AO-A12E-01 | TCGA-AO-A12E-01 | FEMALE | 51.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 57.23 | Luminal A | -7.0 | -5.0 | 1.0 | 3.0 | LumA/B | 3.0 | 3.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
247 | ER+ | ER+ | ER+ | TCGA-E2-A106-01 | TCGA-E2-A106-01 | FEMALE | 34.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IB | No_Conversion | followup | LIVING | 59.37 | Luminal A | -3.0 | 0.0 | 4.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
248 | ER+ | ER+ | ER+ | TCGA-A2-A0CV-01 | TCGA-A2-A0CV-01 | FEMALE | 41.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 63.38 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | LumA/B | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
249 | HER2+ | ER+ | ER+/HER2+ | TCGA-AO-A12C-01 | TCGA-AO-A12C-01 | FEMALE | 42.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 65.48 | Luminal A | -7.0 | -5.0 | 6.0 | 4.0 | ReacI | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
250 | TNBC | TNBC | TNBC | TCGA-B6-A0RG-01 | TCGA-B6-A0RG-01 | FEMALE | 26.0 | Negative | Negative | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 68.40 | Luminal A | -3.0 | 0.0 | 4.0 | 2.0 | ReacII | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
251 | ER+ | ER+ | ER+ | TCGA-A2-A0CS-01 | TCGA-A2-A0CS-01 | FEMALE | 73.0 | Positive | Positive | Negative | T4 | T_Other | N3 | Positive | M1 | Positive | Stage IV | No_Conversion | followup | LIVING | 75.50 | Luminal A | -3.0 | -12.0 | 4.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
252 | ER+ | ER+ | ER+ | TCGA-A2-A0EO-01 | TCGA-A2-A0EO-01 | FEMALE | 54.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 80.20 | Luminal A | -7.0 | -5.0 | 2.0 | 4.0 | LumA | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
253 | ER+ | ER+ | ER+ | TCGA-A2-A0CQ-01 | TCGA-A2-A0CQ-01 | FEMALE | 62.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 88.51 | Luminal A | -3.0 | -12.0 | 2.0 | 4.0 | LumA/B | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
254 | ER+ | ER+ | ER+ | TCGA-A2-A0EN-01 | TCGA-A2-A0EN-01 | FEMALE | 70.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 89.27 | Luminal A | -7.0 | -5.0 | 2.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
255 | ER+ | ER+ | ER+ | TCGA-AO-A12A-01 | TCGA-AO-A12A-01 | FEMALE | 47.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 90.48 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
256 | ER+ | ER+ | ER+ | TCGA-A2-A0CP-01 | TCGA-A2-A0CP-01 | FEMALE | 60.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 92.42 | Luminal A | -7.0 | -5.0 | 4.0 | 1.0 | X | 4.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
257 | ER+ | ER+ | ER+ | TCGA-AO-A126-01 | TCGA-AO-A126-01 | FEMALE | 39.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 93.64 | Luminal A | -3.0 | 0.0 | 6.0 | 4.0 | Her2 | 5.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
258 | ER+ | ER+ | ER+ | TCGA-AO-A125-01 | TCGA-AO-A125-01 | FEMALE | 72.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 99.16 | Luminal A | -3.0 | -12.0 | 3.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
259 | ER+ | ER+ | ER+ | TCGA-A2-A0EM-01 | TCGA-A2-A0EM-01 | FEMALE | 73.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 101.62 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
260 | ER+ | ER+ | ER+ | TCGA-A2-A04N-01 | TCGA-A2-A04N-01 | FEMALE | 66.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 104.74 | Luminal A | -3.0 | -5.0 | 6.0 | 2.0 | LumA | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
261 | HER2+ | ER+ | ER+/HER2+ | TCGA-AQ-A04L-01 | TCGA-AQ-A04L-01 | FEMALE | 48.0 | Positive | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 109.87 | Luminal A | -5.0 | -1.0 | 3.0 | 3.0 | ReacI | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
262 | ER+ | ER+ | ER+ | TCGA-B6-A0IO-01 | TCGA-B6-A0IO-01 | FEMALE | 66.0 | Positive | Indeterminate | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 110.06 | Luminal A | -3.0 | 0.0 | 1.0 | 2.0 | X | 3.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
263 | ER+ | ER+ | ER+ | TCGA-B6-A0IP-01 | TCGA-B6-A0IP-01 | FEMALE | 74.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 110.85 | Luminal A | 0.0 | -5.0 | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
264 | ER+ | ER+ | ER+ | TCGA-B6-A0WZ-01 | TCGA-B6-A0WZ-01 | FEMALE | 50.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 129.48 | Luminal A | -3.0 | -12.0 | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
265 | ER+ | ER+ | ER+ | TCGA-B6-A0I5-01 | TCGA-B6-A0I5-01 | FEMALE | 49.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 149.46 | Luminal A | -3.0 | -5.0 | 6.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
266 | ER+ | ER+ | ER+ | TCGA-B6-A0RV-01 | TCGA-B6-A0RV-01 | FEMALE | 42.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 157.31 | Luminal A | 0.0 | -5.0 | 6.0 | 1.0 | ReacII | 4.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
267 | ER+ | ER+ | ER+ | TCGA-B6-A0RO-01 | TCGA-B6-A0RO-01 | FEMALE | 71.0 | Positive | Positive | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | No_Conversion | followup | LIVING | 161.91 | Luminal A | -3.0 | 0.0 | 1.0 | 2.0 | ReacI | 3.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
268 | TNBC | TNBC | TNBC | TCGA-B6-A0RN-01 | TCGA-B6-A0RN-01 | FEMALE | 60.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 172.85 | Luminal A | -3.0 | -5.0 | 2.0 | 4.0 | ReacI | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
269 | ER+ | ER+ | ER+ | TCGA-B6-A0WT-01 | TCGA-B6-A0WT-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 188.55 | Luminal A | -4.0 | -2.0 | 4.0 | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
270 | ER+ | ER+ | ER+ | TCGA-B6-A0IA-01 | TCGA-B6-A0IA-01 | FEMALE | 51.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 220.72 | Luminal A | -3.0 | -12.0 | 4.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
271 | ER+ | ER+ | ER+ | TCGA-B6-A0RI-01 | TCGA-B6-A0RI-01 | FEMALE | 44.0 | Positive | Positive | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | No_Conversion | followup | LIVING | 234.09 | Luminal A | -3.0 | -7.0 | 4.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
272 | ER+ | ER+ | ER+ | TCGA-A1-A0SE-01 | TCGA-A1-A0SE-01 | FEMALE | 56.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 43.37 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
273 | ER+ | ER+ | ER+ | TCGA-A2-A0EX-01 | TCGA-A2-A0EX-01 | FEMALE | 46.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 18.04 | Luminal A | -7.0 | -5.0 | 4.0 | 4.0 | ReacI | 4.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
274 | ER+ | ER+ | ER+ | TCGA-AO-A0JJ-01 | TCGA-AO-A0JJ-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 49.68 | Luminal A | -7.0 | -5.0 | 7.0 | 1.0 | LumA/B | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
275 | ER+ | ER+ | ER+ | TCGA-E2-A105-01 | TCGA-E2-A105-01 | FEMALE | 79.0 | Positive | Positive | Equivocal | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 38.21 | Luminal A | -3.0 | -10.0 | 1.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
276 | ER+ | ER+ | ER+ | TCGA-A1-A0SD-01 | TCGA-A1-A0SD-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 14.36 | Luminal A | -3.0 | -9.0 | 6.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
277 | NaN | NaN | NaN | TCGA-A1-A0SH-01 | TCGA-A1-A0SH-01 | FEMALE | 39.0 | Negative | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 47.21 | Luminal A | -7.0 | -5.0 | 4.0 | 2.0 | Her2 | 5.0 | 1.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
278 | ER+ | ER+ | ER+ | TCGA-A1-A0SJ-01 | TCGA-A1-A0SJ-01 | FEMALE | 39.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 14.00 | Luminal A | -3.0 | -3.0 | 4.0 | 4.0 | ReacI | 3.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
279 | ER+ | ER+ | ER+ | TCGA-A8-A06P-01 | TCGA-A8-A06P-01 | FEMALE | 63.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 13.01 | Luminal A | -3.0 | -5.0 | 4.0 | 2.0 | ReacI | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
280 | ER+ | ER+ | ER+ | TCGA-A8-A06T-01 | TCGA-A8-A06T-01 | FEMALE | 75.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 41.04 | Luminal A | -3.0 | -10.0 | 2.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
281 | ER+ | ER+ | ER+ | TCGA-A8-A06Y-01 | TCGA-A8-A06Y-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 25.99 | Luminal A | -3.0 | 0.0 | 2.0 | 4.0 | LumA | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
282 | ER+ | ER+ | ER+ | TCGA-A8-A07E-01 | TCGA-A8-A07E-01 | FEMALE | 81.0 | Positive | Positive | Negative | T4 | T_Other | N3 | Positive | M0 | Negative | Stage X | Stage IIIC | enrollment | LIVING | 19.98 | Luminal A | -3.0 | -4.0 | 1.0 | 4.0 | ReacII | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
283 | ER+ | ER+ | ER+ | TCGA-A8-A07F-01 | TCGA-A8-A07F-01 | FEMALE | 65.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 18.92 | Luminal A | -1.0 | -1.0 | 4.0 | 4.0 | ReacI | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
284 | ER+ | ER+ | ER+ | TCGA-A8-A07G-01 | TCGA-A8-A07G-01 | FEMALE | 65.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 18.92 | Luminal A | -7.0 | -5.0 | 4.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
285 | ER+ | ER+ | ER+ | TCGA-A8-A07J-01 | TCGA-A8-A07J-01 | FEMALE | 35.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 11.99 | Luminal A | -7.0 | -5.0 | 4.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
286 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A07P-01 | TCGA-A8-A07P-01 | FEMALE | 68.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 10.97 | Luminal A | -3.0 | -10.0 | 2.0 | 3.0 | LumA/B | 4.0 | 3.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
287 | ER+ | ER+ | ER+ | TCGA-A8-A083-01 | TCGA-A8-A083-01 | FEMALE | 67.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
288 | ER+ | ER+ | ER+ | TCGA-A8-A086-01 | TCGA-A8-A086-01 | FEMALE | 59.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 13.01 | Luminal A | -3.0 | -9.0 | 5.0 | 2.0 | LumA | 5.0 | 3.0 | 2.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
289 | ER+ | ER+ | ER+ | TCGA-A8-A08A-01 | TCGA-A8-A08A-01 | FEMALE | 89.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 0.99 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
290 | ER+ | ER+ | ER+ | TCGA-A8-A08C-01 | TCGA-A8-A08C-01 | FEMALE | 65.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.94 | Luminal A | -3.0 | -12.0 | NaN | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
291 | ER+ | ER+ | ER+ | TCGA-A8-A08O-01 | TCGA-A8-A08O-01 | FEMALE | 45.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M1 | Positive | Stage IV | Stage IV | enrollment | LIVING | 30.95 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
292 | ER+ | ER+ | ER+ | TCGA-A8-A08T-01 | TCGA-A8-A08T-01 | FEMALE | 64.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M1 | Positive | Stage IV | Stage IV | enrollment | LIVING | 92.98 | Luminal A | -3.0 | -5.0 | 2.0 | 4.0 | LumA | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
293 | ER+ | ER+ | ER+ | TCGA-A8-A08Z-01 | TCGA-A8-A08Z-01 | FEMALE | 76.0 | Positive | Positive | Negative | T4 | T_Other | N3 | Positive | M0 | Negative | Stage IIIB | Stage IIIC | enrollment | LIVING | 39.98 | Luminal A | -3.0 | -5.0 | 4.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
294 | ER+ | ER+ | ER+ | TCGA-A8-A090-01 | TCGA-A8-A090-01 | FEMALE | 74.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Luminal A | -3.0 | 0.0 | 2.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
295 | ER+ | ER+ | ER+ | TCGA-A8-A091-01 | TCGA-A8-A091-01 | FEMALE | 61.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.06 | Luminal A | -3.0 | -10.0 | 2.0 | 4.0 | LumA/B | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
296 | ER+ | ER+ | ER+ | TCGA-A8-A093-01 | TCGA-A8-A093-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 17.91 | Luminal A | -3.0 | -12.0 | 2.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
297 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A099-01 | TCGA-A8-A099-01 | FEMALE | 76.0 | Positive | Positive | Positive | T4 | T_Other | N3 | Positive | M0 | Negative | Stage X | Stage IIIC | enrollment | LIVING | 9.99 | Luminal A | -3.0 | -12.0 | 1.0 | 3.0 | LumA/B | 2.0 | 3.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
298 | ER+ | ER+ | ER+ | TCGA-A8-A09A-01 | TCGA-A8-A09A-01 | FEMALE | 40.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage X | Stage IIA | enrollment | LIVING | 9.99 | Luminal A | -3.0 | -3.0 | 4.0 | 4.0 | LumA | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
299 | ER+ | ER+ | ER+ | TCGA-A8-A09B-01 | TCGA-A8-A09B-01 | FEMALE | 58.0 | Positive | Positive | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 11.99 | Luminal A | -3.0 | 0.0 | 4.0 | 4.0 | LumA | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
300 | ER+ | ER+ | ER+ | TCGA-A8-A09T-01 | TCGA-A8-A09T-01 | FEMALE | 68.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage X | Stage I | enrollment | LIVING | 18.99 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
301 | ER+ | ER+ | ER+ | TCGA-A8-A09V-01 | TCGA-A8-A09V-01 | FEMALE | 51.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 15.01 | Luminal A | -3.0 | -12.0 | NaN | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
302 | ER+ | ER+ | ER+ | TCGA-A8-A0A1-01 | TCGA-A8-A0A1-01 | FEMALE | 84.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 11.99 | Luminal A | -7.0 | -5.0 | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
303 | ER+ | ER+ | ER+ | TCGA-A8-A0A2-01 | TCGA-A8-A0A2-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 18.99 | Luminal A | -3.0 | 0.0 | 2.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
304 | ER+ | ER+ | ER+ | TCGA-A8-A0A4-01 | TCGA-A8-A0A4-01 | FEMALE | 73.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 13.01 | Luminal A | -7.0 | -5.0 | 3.0 | 4.0 | ReacII | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
305 | ER+ | ER+ | ER+ | TCGA-A8-A0A6-01 | TCGA-A8-A0A6-01 | FEMALE | 64.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 21.03 | Luminal A | -4.0 | -5.0 | 1.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
306 | ER+ | ER+ | ER+ | TCGA-A8-A0AD-01 | TCGA-A8-A0AD-01 | FEMALE | 83.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 38.01 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
307 | ER+ | ER+ | ER+ | TCGA-AN-A03X-01 | TCGA-AN-A03X-01 | FEMALE | 74.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.33 | Luminal A | -3.0 | 0.0 | 4.0 | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
308 | ER+ | ER+ | ER+ | TCGA-AN-A046-01 | TCGA-AN-A046-01 | FEMALE | 68.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.33 | Luminal A | -3.0 | 0.0 | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
309 | ER+ | ER+ | ER+ | TCGA-AN-A04A-01 | TCGA-AN-A04A-01 | FEMALE | 36.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | enrollment | LIVING | 2.92 | Luminal A | -3.0 | -5.0 | 4.0 | 2.0 | LumA/B | 5.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
310 | HER2+ | ER+ | ER+/HER2+ | TCGA-AN-A0FD-01 | TCGA-AN-A0FD-01 | FEMALE | 71.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 6.41 | Luminal A | -3.0 | -8.0 | 4.0 | 2.0 | LumA/B | 1.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
311 | ER+ | ER+ | ER+ | TCGA-AN-A0FN-01 | TCGA-AN-A0FN-01 | FEMALE | 61.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IB | No_Conversion | enrollment | LIVING | 7.16 | Luminal A | -7.0 | -5.0 | 4.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
312 | ER+ | ER+ | ER+ | TCGA-AN-A0FS-01 | TCGA-AN-A0FS-01 | FEMALE | 55.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IB | No_Conversion | enrollment | LIVING | 6.28 | Luminal A | -7.0 | -5.0 | 2.0 | 2.0 | ReacII | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
313 | HER2+ | ER+ | ER+/HER2+ | TCGA-AN-A0FT-01 | TCGA-AN-A0FT-01 | FEMALE | 63.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 6.01 | Luminal A | -3.0 | -2.0 | 5.0 | 3.0 | Her2 | 3.0 | 3.0 | 4.0 | 5.0 | Breast Cancer | Invasive Breast Carcinoma |
314 | ER+ | ER+ | ER+ | TCGA-AN-A0FW-01 | TCGA-AN-A0FW-01 | FEMALE | 67.0 | Positive | Indeterminate | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | enrollment | LIVING | 0.36 | Luminal A | -3.0 | -4.0 | 1.0 | 3.0 | LumA/B | 3.0 | 3.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
315 | ER+ | ER+ | ER+ | TCGA-AN-A0FZ-01 | TCGA-AN-A0FZ-01 | FEMALE | 45.0 | Positive | Negative | Equivocal | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | enrollment | LIVING | 0.33 | Luminal A | -3.0 | -3.0 | 4.0 | 2.0 | LumA/B | 3.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
316 | ER+ | ER+ | ER+ | TCGA-AN-A0XL-01 | TCGA-AN-A0XL-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.33 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
317 | NaN | NaN | NaN | TCGA-AN-A0XN-01 | TCGA-AN-A0XN-01 | FEMALE | 68.0 | Negative | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.33 | Luminal A | -3.0 | -5.0 | 4.0 | 3.0 | ReacI | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
318 | ER+ | ER+ | ER+ | TCGA-AN-A0XO-01 | TCGA-AN-A0XO-01 | FEMALE | 59.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 12.32 | Luminal A | -3.0 | -7.0 | 4.0 | 4.0 | LumA/B | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
319 | ER+ | ER+ | ER+ | TCGA-AN-A0XP-01 | TCGA-AN-A0XP-01 | FEMALE | 69.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.30 | Luminal A | -3.0 | -12.0 | 4.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
320 | NaN | NaN | NaN | TCGA-AN-A0XS-01 | TCGA-AN-A0XS-01 | FEMALE | 63.0 | Negative | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.33 | Luminal A | -4.0 | -5.0 | 4.0 | 2.0 | LumA | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
321 | ER+ | ER+ | ER+ | TCGA-AN-A0XT-01 | TCGA-AN-A0XT-01 | FEMALE | 54.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.33 | Luminal A | -3.0 | 0.0 | 7.0 | 5.0 | LumA/B | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
322 | ER+ | ER+ | ER+ | TCGA-AN-A0XV-01 | TCGA-AN-A0XV-01 | FEMALE | 67.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 5.32 | Luminal A | 0.0 | 0.0 | 2.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
323 | ER+ | ER+ | ER+ | TCGA-AR-A0TW-01 | TCGA-AR-A0TW-01 | FEMALE | 50.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage III | No_Conversion | enrollment | LIVING | 24.28 | Luminal A | -5.0 | -2.0 | NaN | 4.0 | Basal | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
324 | ER+ | ER+ | ER+ | TCGA-AR-A1AK-01 | TCGA-AR-A1AK-01 | FEMALE | 70.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 51.19 | Luminal A | 0.0 | -5.0 | 4.0 | 1.0 | ReacI | 3.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
325 | ER+ | ER+ | ER+ | TCGA-AR-A1AL-01 | TCGA-AR-A1AL-01 | FEMALE | 60.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 48.79 | Luminal A | 0.0 | -4.0 | 6.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
326 | ER+ | ER+ | ER+ | TCGA-AR-A1AN-01 | TCGA-AR-A1AN-01 | FEMALE | 46.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 43.66 | Luminal A | -7.0 | -5.0 | 6.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
327 | ER+ | ER+ | ER+ | TCGA-AR-A1AP-01 | TCGA-AR-A1AP-01 | FEMALE | 80.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 39.92 | Luminal A | 0.0 | 0.0 | 4.0 | 4.0 | LumA/B | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
328 | ER+ | ER+ | ER+ | TCGA-AR-A1AS-01 | TCGA-AR-A1AS-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 40.81 | Luminal A | -3.0 | -7.0 | 4.0 | 2.0 | LumA | 3.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
329 | ER+ | ER+ | ER+ | TCGA-AR-A1AU-01 | TCGA-AR-A1AU-01 | FEMALE | 39.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 46.29 | Luminal A | -7.0 | -3.0 | 6.0 | 2.0 | ReacI | 4.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
330 | ER+ | ER+ | ER+ | TCGA-AR-A1AW-01 | TCGA-AR-A1AW-01 | FEMALE | 65.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 35.22 | Luminal A | -3.0 | -12.0 | 3.0 | 1.0 | ReacII | 3.0 | 3.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
331 | HER2+ | ER+ | ER+/HER2+ | TCGA-AR-A1AX-01 | TCGA-AR-A1AX-01 | FEMALE | 64.0 | Positive | Positive | Positive | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 36.24 | Luminal A | -5.0 | 0.0 | 6.0 | 5.0 | ReacII | 4.0 | 3.0 | 3.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
332 | ER+ | ER+ | ER+ | TCGA-BH-A0AZ-01 | TCGA-BH-A0AZ-01 | FEMALE | 47.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 28.49 | Luminal A | -7.0 | -5.0 | 4.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
333 | ER+ | ER+ | ER+ | TCGA-BH-A0B0-01 | TCGA-BH-A0B0-01 | FEMALE | 56.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 46.88 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
334 | ER+ | ER+ | ER+ | TCGA-BH-A0BM-01 | TCGA-BH-A0BM-01 | FEMALE | 54.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 36.70 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
335 | ER+ | ER+ | ER+ | TCGA-BH-A0BO-01 | TCGA-BH-A0BO-01 | FEMALE | 54.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 35.65 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 1.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
336 | ER+ | ER+ | ER+ | TCGA-BH-A0BP-01 | TCGA-BH-A0BP-01 | FEMALE | 76.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 48.66 | Luminal A | -7.0 | -5.0 | 4.0 | 4.0 | ReacI | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
337 | ER+ | ER+ | ER+ | TCGA-BH-A0BQ-01 | TCGA-BH-A0BQ-01 | FEMALE | 39.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 27.14 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | Her2 | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
338 | ER+ | ER+ | ER+ | TCGA-BH-A0BR-01 | TCGA-BH-A0BR-01 | FEMALE | 59.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 53.62 | Luminal A | -3.0 | -4.0 | 4.0 | 4.0 | ReacI | 1.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
339 | ER+ | ER+ | ER+ | TCGA-BH-A0BS-01 | TCGA-BH-A0BS-01 | FEMALE | 55.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 53.88 | Luminal A | -2.0 | 0.0 | 7.0 | 2.0 | LumA/B | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
340 | ER+ | ER+ | ER+ | TCGA-BH-A0BT-01 | TCGA-BH-A0BT-01 | FEMALE | 56.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 45.54 | Luminal A | -3.0 | -12.0 | 6.0 | 2.0 | ReacII | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
341 | ER+ | ER+ | ER+ | TCGA-BH-A0C1-01 | TCGA-BH-A0C1-01 | FEMALE | 61.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 43.96 | Luminal A | -1.0 | -1.0 | 5.0 | 4.0 | ReacII | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
342 | ER+ | ER+ | ER+ | TCGA-BH-A0DE-01 | TCGA-BH-A0DE-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 31.15 | Luminal A | -7.0 | -5.0 | 6.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
343 | ER+ | ER+ | ER+ | TCGA-BH-A0DG-01 | TCGA-BH-A0DG-01 | FEMALE | 30.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 23.43 | Luminal A | -4.0 | -4.0 | 4.0 | 1.0 | ReacI | 3.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
344 | ER+ | ER+ | ER+ | TCGA-BH-A0DI-01 | TCGA-BH-A0DI-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 22.11 | Luminal A | -7.0 | -5.0 | 4.0 | 1.0 | ReacI | 5.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
345 | ER+ | ER+ | ER+ | TCGA-BH-A0DO-01 | TCGA-BH-A0DO-01 | FEMALE | 78.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 17.25 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
346 | ER+ | ER+ | ER+ | TCGA-BH-A0DT-01 | TCGA-BH-A0DT-01 | FEMALE | 41.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 38.44 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | LumA | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
347 | ER+ | ER+ | ER+ | TCGA-BH-A0DX-01 | TCGA-BH-A0DX-01 | FEMALE | 62.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 47.38 | Luminal A | -7.0 | -4.0 | 6.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
348 | ER+ | ER+ | ER+ | TCGA-BH-A0E9-01 | TCGA-BH-A0E9-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 46.16 | Luminal A | -7.0 | -5.0 | 6.0 | 1.0 | ReacI | 3.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
349 | ER+ | ER+ | ER+ | TCGA-BH-A0EI-01 | TCGA-BH-A0EI-01 | FEMALE | 51.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 24.41 | Luminal A | -7.0 | -5.0 | 4.0 | 4.0 | LumA | 5.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
350 | ER+ | ER+ | ER+ | TCGA-BH-A0H3-01 | TCGA-BH-A0H3-01 | FEMALE | 46.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 37.75 | Luminal A | -4.0 | -2.0 | 6.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
351 | ER+ | ER+ | ER+ | TCGA-BH-A0H5-01 | TCGA-BH-A0H5-01 | FEMALE | 45.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 35.48 | Luminal A | -5.0 | -2.0 | 3.0 | 1.0 | Basal | 1.0 | 1.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
352 | ER+ | ER+ | ER+ | TCGA-BH-A0HA-01 | TCGA-BH-A0HA-01 | FEMALE | 31.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 28.12 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | ReacI | 1.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
353 | ER+ | ER+ | ER+ | TCGA-BH-A0W4-01 | TCGA-BH-A0W4-01 | FEMALE | 46.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 5.75 | Luminal A | -7.0 | -5.0 | 4.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
354 | ER+ | ER+ | ER+ | TCGA-BH-A0W5-01 | TCGA-BH-A0W5-01 | FEMALE | 77.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 17.84 | Luminal A | -4.0 | -5.0 | 4.0 | 1.0 | LumA | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
355 | ER+ | ER+ | ER+ | TCGA-BH-A0W7-01 | TCGA-BH-A0W7-01 | FEMALE | 49.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 18.33 | Luminal A | -4.0 | -4.0 | 4.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
356 | ER+ | ER+ | ER+ | TCGA-BH-A18H-01 | TCGA-BH-A18H-01 | FEMALE | 63.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IB | Stage I | enrollment | LIVING | 0.00 | Luminal A | -5.0 | -2.0 | 6.0 | 1.0 | LumA/B | 3.0 | 3.0 | 3.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
357 | ER+ | ER+ | ER+ | TCGA-BH-A18I-01 | TCGA-BH-A18I-01 | FEMALE | 53.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 7.23 | Luminal A | -4.0 | -5.0 | 4.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
358 | ER+ | ER+ | ER+ | TCGA-C8-A12N-01 | TCGA-C8-A12N-01 | FEMALE | 58.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Luminal A | -3.0 | -12.0 | 6.0 | 2.0 | ReacI | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
359 | ER+ | ER+ | ER+ | TCGA-C8-A12O-01 | TCGA-C8-A12O-01 | FEMALE | 50.0 | Positive | Positive | Not Available | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Luminal A | 0.0 | -2.0 | 4.0 | 1.0 | Her2 | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
360 | NaN | NaN | NaN | TCGA-C8-A12Y-01 | TCGA-C8-A12Y-01 | FEMALE | 44.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | Luminal A | -3.0 | 0.0 | 6.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
361 | HER2+ | ER+ | ER+/HER2+ | TCGA-C8-A132-01 | TCGA-C8-A132-01 | FEMALE | 56.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 0.00 | Luminal A | -4.0 | -2.0 | 5.0 | 1.0 | Her2 | 5.0 | 3.0 | 2.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
362 | ER+ | ER+ | ER+ | TCGA-C8-A133-01 | TCGA-C8-A133-01 | FEMALE | 65.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.00 | Luminal A | -3.0 | -12.0 | 1.0 | 2.0 | LumA/B | 1.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
363 | ER+ | ER+ | ER+ | TCGA-C8-A1HI-01 | TCGA-C8-A1HI-01 | FEMALE | 40.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.07 | Luminal A | 0.0 | -5.0 | 6.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
364 | ER+ | ER+ | ER+ | TCGA-D8-A141-01 | TCGA-D8-A141-01 | FEMALE | 40.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage X | Stage IIA | enrollment | LIVING | 3.71 | Luminal A | -4.0 | -5.0 | 4.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
365 | ER+ | ER+ | ER+ | TCGA-E2-A14Q-01 | TCGA-E2-A14Q-01 | FEMALE | 50.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | Stage IIB | enrollment | LIVING | 32.00 | Luminal A | -7.0 | 0.0 | 2.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
366 | ER+ | ER+ | ER+ | TCGA-E2-A14T-01 | TCGA-E2-A14T-01 | FEMALE | 52.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 29.24 | Luminal A | -3.0 | 0.0 | 1.0 | 2.0 | LumA/B | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
367 | ER+ | ER+ | ER+ | TCGA-E2-A14Z-01 | TCGA-E2-A14Z-01 | FEMALE | 64.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 17.02 | Luminal A | -2.0 | 0.0 | 6.0 | 1.0 | LumA | 1.0 | 3.0 | 3.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
368 | ER+ | ER+ | ER+ | TCGA-E2-A153-01 | TCGA-E2-A153-01 | FEMALE | 51.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIB | Stage IIA | enrollment | LIVING | 19.25 | Luminal A | -3.0 | -12.0 | 4.0 | 1.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
369 | ER+ | ER+ | ER+ | TCGA-E2-A154-01 | TCGA-E2-A154-01 | FEMALE | 68.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 10.68 | Luminal A | -3.0 | -12.0 | 6.0 | 4.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
370 | ER+ | ER+ | ER+ | TCGA-E2-A156-01 | TCGA-E2-A156-01 | FEMALE | 61.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 15.80 | Luminal A | -3.0 | -12.0 | 2.0 | 2.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
371 | ER+ | ER+ | ER+ | TCGA-E2-A15C-01 | TCGA-E2-A15C-01 | FEMALE | 61.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 16.30 | Luminal A | -4.0 | -5.0 | 2.0 | 2.0 | ReacI | 4.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
372 | ER+ | ER+ | ER+ | TCGA-E2-A15D-01 | TCGA-E2-A15D-01 | FEMALE | 47.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 10.35 | Luminal A | -3.0 | -5.0 | 4.0 | 1.0 | LumA | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
373 | HER2+ | ER+ | ER+/HER2+ | TCGA-E2-A15E-01 | TCGA-E2-A15E-01 | FEMALE | 40.0 | Positive | Positive | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 16.99 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | Her2 | 4.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
374 | ER+ | ER+ | ER+ | TCGA-E2-A15F-01 | TCGA-E2-A15F-01 | FEMALE | 64.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage I | Stage IIA | enrollment | LIVING | 15.38 | Luminal A | -3.0 | -3.0 | 4.0 | 2.0 | ReacI | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
375 | ER+ | ER+ | ER+ | TCGA-E2-A15G-01 | TCGA-E2-A15G-01 | FEMALE | 76.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 10.35 | Luminal A | -3.0 | -12.0 | 1.0 | 1.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
376 | HER2+ | ER+ | ER+/HER2+ | TCGA-E2-A15H-01 | TCGA-E2-A15H-01 | FEMALE | 38.0 | Positive | Positive | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 1.38 | Luminal A | 0.0 | 0.0 | 4.0 | 2.0 | Her2 | 2.0 | 3.0 | 3.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
377 | ER+ | ER+ | ER+ | TCGA-E2-A15I-01 | TCGA-E2-A15I-01 | FEMALE | 44.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 13.50 | Luminal A | -7.0 | -5.0 | 7.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
378 | ER+ | ER+ | ER+ | TCGA-E2-A15J-01 | TCGA-E2-A15J-01 | FEMALE | 51.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 15.21 | Luminal A | -3.0 | -12.0 | 4.0 | 4.0 | LumA/B | 2.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
379 | ER+ | ER+ | ER+ | TCGA-E2-A15O-01 | TCGA-E2-A15O-01 | FEMALE | 89.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage I | Stage IIA | enrollment | LIVING | 12.98 | Luminal A | -3.0 | 0.0 | 2.0 | 4.0 | LumA | 4.0 | 3.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
380 | ER+ | ER+ | ER+ | TCGA-E2-A15P-01 | TCGA-E2-A15P-01 | FEMALE | 61.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 10.35 | Luminal A | -7.0 | -5.0 | 2.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
381 | ER+ | ER+ | ER+ | TCGA-E2-A15R-01 | TCGA-E2-A15R-01 | FEMALE | 64.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIA | enrollment | LIVING | 10.84 | Luminal A | -3.0 | -10.0 | 5.0 | 3.0 | LumA/B | 4.0 | 3.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
382 | HER2+ | ER+ | ER+/HER2+ | TCGA-E2-A1B1-01 | TCGA-E2-A1B1-01 | FEMALE | 45.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 44.72 | Luminal A | -7.0 | -5.0 | 4.0 | 5.0 | ReacI | 3.0 | 3.0 | 1.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
383 | ER+ | ER+ | ER+ | TCGA-E2-A1B4-01 | TCGA-E2-A1B4-01 | FEMALE | 74.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 29.93 | Luminal A | -3.0 | -12.0 | 6.0 | 2.0 | LumA/B | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
384 | TNBC | TNBC | TNBC | TCGA-E2-A1B6-01 | TCGA-E2-A1B6-01 | FEMALE | 44.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 11.10 | Luminal A | -7.0 | -5.0 | 6.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
385 | ER+ | ER+ | ER+ | TCGA-E2-A1BC-01 | TCGA-E2-A1BC-01 | FEMALE | 63.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 9.76 | Luminal A | -7.0 | -5.0 | 6.0 | 2.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
386 | ER+ | ER+ | ER+ | TCGA-E2-A1BD-01 | TCGA-E2-A1BD-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 10.42 | Luminal A | -3.0 | -7.0 | 6.0 | 4.0 | LumA | 2.0 | 3.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
387 | ER+ | ER+ | ER+ | TCGA-A2-A0SV-01 | TCGA-A2-A0SV-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M1 | Positive | Stage IV | No_Conversion | followup | DECEASED | 27.11 | Luminal B | -3.0 | -2.0 | 6.0 | 2.0 | Basal | 5.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
388 | ER+ | ER+ | ER+ | TCGA-AO-A03O-01 | TCGA-AO-A03O-01 | FEMALE | 69.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | DECEASED | 81.58 | Luminal B | -5.0 | -2.0 | 1.0 | 4.0 | LumA/B | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
389 | ER+ | ER+ | ER+ | TCGA-A2-A0SW-01 | TCGA-A2-A0SW-01 | FEMALE | 82.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M1 | Positive | Stage IV | No_Conversion | followup | DECEASED | 44.81 | Luminal B | -5.0 | -2.0 | 3.0 | 4.0 | Basal | 4.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
390 | ER+ | ER+ | ER+ | TCGA-B6-A0WW-01 | TCGA-B6-A0WW-01 | FEMALE | 58.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | NaN | NaN | NaN | No_Conversion | followup | DECEASED | 18.30 | Luminal B | -3.0 | 0.0 | 2.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
391 | ER+ | ER+ | ER+ | TCGA-BH-A18J-01 | TCGA-BH-A18J-01 | FEMALE | 56.0 | Positive | Positive | Negative | T4 | T_Other | N2 | Positive | M1 | Positive | Stage IV | No_Conversion | enrollment | DECEASED | 20.07 | Luminal B | -3.0 | -1.0 | 4.0 | 1.0 | ReacII | 2.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
392 | ER+ | ER+ | ER+ | TCGA-BH-A18L-01 | TCGA-BH-A18L-01 | FEMALE | 50.0 | Positive | Positive | Not Available | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIIA | enrollment | DECEASED | 26.65 | Luminal B | -5.0 | -10.0 | 1.0 | 4.0 | ReacII | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
393 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A06X-01 | TCGA-A8-A06X-01 | FEMALE | 77.0 | Positive | Negative | Positive | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | DECEASED | 30.98 | Luminal B | -5.0 | -2.0 | NaN | 3.0 | LumA/B | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
394 | ER+ | ER+ | ER+ | TCGA-B6-A0IC-01 | TCGA-B6-A0IC-01 | FEMALE | 90.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | NaN | NaN | NaN | No_Conversion | followup | DECEASED | 50.66 | Luminal B | -3.0 | -12.0 | 2.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
395 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A18U-01 | TCGA-BH-A18U-01 | FEMALE | 72.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | DECEASED | 51.35 | Luminal B | -5.0 | -2.0 | 5.0 | 3.0 | ReacI | 3.0 | 4.0 | 4.0 | 5.0 | Breast Cancer | Invasive Breast Carcinoma |
396 | TNBC | TNBC | TNBC | TCGA-BH-A1EW-01 | TCGA-BH-A1EW-01 | FEMALE | 38.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | enrollment | DECEASED | 55.66 | Luminal B | -3.0 | -3.0 | 6.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
397 | ER+ | ER+ | ER+ | TCGA-AR-A0TY-01 | TCGA-AR-A0TY-01 | FEMALE | 54.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | No_Conversion | enrollment | DECEASED | 55.82 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | LumA/B | 1.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
398 | ER+ | ER+ | ER+ | TCGA-B6-A0X5-01 | TCGA-B6-A0X5-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | DECEASED | 68.90 | Luminal B | -3.0 | 0.0 | 1.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
399 | ER+ | ER+ | ER+ | TCGA-B6-A0WV-01 | TCGA-B6-A0WV-01 | FEMALE | 67.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | DECEASED | 79.57 | Luminal B | -3.0 | 0.0 | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
400 | ER+ | ER+ | ER+ | TCGA-B6-A0RL-01 | TCGA-B6-A0RL-01 | FEMALE | 60.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | DECEASED | 81.12 | Luminal B | -3.0 | -10.0 | 5.0 | 3.0 | LumA/B | 2.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
401 | ER+ | ER+ | ER+ | TCGA-AR-A0U2-01 | TCGA-AR-A0U2-01 | FEMALE | 47.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | No_Conversion | enrollment | DECEASED | 83.81 | Luminal B | -5.0 | -10.0 | 5.0 | 2.0 | ReacII | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
402 | ER+ | ER+ | ER+ | TCGA-B6-A0IB-01 | TCGA-B6-A0IB-01 | FEMALE | 64.0 | Positive | Positive | Negative | T3 | T_Other | N3 | Positive | M1 | Positive | Stage IV | No_Conversion | followup | DECEASED | 129.48 | Luminal B | -3.0 | 0.0 | 1.0 | 4.0 | LumA/B | 4.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
403 | ER+ | ER+ | ER+ | TCGA-AO-A0J7-01 | TCGA-AO-A0J7-01 | FEMALE | 71.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 8.54 | Luminal B | -3.0 | 0.0 | 2.0 | 4.0 | LumA/B | 2.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
404 | ER+ | ER+ | ER+ | TCGA-AO-A0J3-01 | TCGA-AO-A0J3-01 | FEMALE | 67.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 9.92 | Luminal B | -3.0 | -10.0 | 1.0 | 3.0 | LumA/B | 5.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
405 | ER+ | ER+ | ER+ | TCGA-D8-A13Y-01 | TCGA-D8-A13Y-01 | FEMALE | 52.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | No_Conversion | followup | LIVING | 11.89 | Luminal B | -6.0 | -2.0 | 1.0 | 2.0 | Basal | 5.0 | 4.0 | 3.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
406 | ER+ | ER+ | ER+ | TCGA-A7-A13F-01 | TCGA-A7-A13F-01 | FEMALE | 44.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 12.71 | Luminal B | -3.0 | 0.0 | 4.0 | 4.0 | LumA/B | 3.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
407 | ER+ | ER+ | ER+ | TCGA-BH-A0HU-01 | TCGA-BH-A0HU-01 | FEMALE | 52.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 12.88 | Luminal B | -3.0 | -2.0 | 4.0 | 2.0 | Her2 | 2.0 | 4.0 | 3.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
408 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A140-01 | TCGA-D8-A140-01 | FEMALE | 62.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 13.24 | Luminal B | -5.0 | -10.0 | 6.0 | 3.0 | LumA/B | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
409 | ER+ | ER+ | ER+ | TCGA-A7-A0CJ-01 | TCGA-A7-A0CJ-01 | FEMALE | 57.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 13.44 | Luminal B | -3.0 | -6.0 | 2.0 | 3.0 | LumA/B | 1.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
410 | HER2+ | ER+ | ER+/HER2+ | TCGA-AQ-A04H-01 | TCGA-AQ-A04H-01 | FEMALE | 61.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | NaN | NaN | Stage IIIA | No_Conversion | followup | LIVING | 14.42 | Luminal B | -3.0 | -10.0 | 7.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
411 | ER+ | ER+ | ER+ | TCGA-BH-A0H0-01 | TCGA-BH-A0H0-01 | FEMALE | 69.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 15.15 | Luminal B | -3.0 | -10.0 | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
412 | ER+ | ER+ | ER+ | TCGA-BH-A0BD-01 | TCGA-BH-A0BD-01 | FEMALE | 47.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 18.20 | Luminal B | 0.0 | 0.0 | 4.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
413 | ER+ | ER+ | ER+ | TCGA-A2-A0T3-01 | TCGA-A2-A0T3-01 | FEMALE | 37.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IA | Stage IIA | followup | LIVING | 18.69 | Luminal B | -3.0 | 0.0 | 7.0 | 3.0 | ReacII | 3.0 | 4.0 | 4.0 | 5.0 | Breast Cancer | Invasive Breast Carcinoma |
414 | ER+ | ER+ | ER+ | TCGA-A2-A0T4-01 | TCGA-A2-A0T4-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 20.50 | Luminal B | -7.0 | -5.0 | 4.0 | 4.0 | ReacI | 2.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
415 | ER+ | ER+ | ER+ | TCGA-A2-A0YH-01 | TCGA-A2-A0YH-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 21.62 | Luminal B | -5.0 | -2.0 | 4.0 | 2.0 | LumA/B | 4.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
416 | HER2+ | ER+ | ER+/HER2+ | TCGA-A2-A0YG-01 | TCGA-A2-A0YG-01 | FEMALE | 63.0 | Positive | Positive | Positive | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | No_Conversion | followup | LIVING | 21.85 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | Her2 | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
417 | HER2+ | ER+ | ER+/HER2+ | TCGA-A2-A0EY-01 | TCGA-A2-A0EY-01 | FEMALE | 62.0 | Positive | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 24.15 | Luminal B | -5.0 | -2.0 | 1.0 | 4.0 | Her2 | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
418 | ER+ | ER+ | ER+ | TCGA-A2-A0D4-01 | TCGA-A2-A0D4-01 | FEMALE | 37.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 25.20 | Luminal B | -3.0 | -10.0 | 5.0 | 3.0 | LumA/B | 5.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
419 | ER+ | ER+ | ER+ | TCGA-BH-A0AY-01 | TCGA-BH-A0AY-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 25.53 | Luminal B | -3.0 | -1.0 | 4.0 | 1.0 | ReacI | 3.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
420 | ER+ | ER+ | ER+ | TCGA-E2-A107-01 | TCGA-E2-A107-01 | FEMALE | 54.0 | Positive | Negative | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 34.37 | Luminal B | -3.0 | 0.0 | 4.0 | 4.0 | LumA/B | 2.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
421 | ER+ | ER+ | ER+ | TCGA-AO-A0JI-01 | TCGA-AO-A0JI-01 | FEMALE | 56.0 | Positive | Negative | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 38.51 | Luminal B | -3.0 | -10.0 | 2.0 | 3.0 | LumA/B | 4.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
422 | ER+ | ER+ | ER+ | TCGA-E2-A10C-01 | TCGA-E2-A10C-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 40.05 | Luminal B | -5.0 | -2.0 | 7.0 | 4.0 | ReacI | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
423 | ER+ | ER+ | ER+ | TCGA-E2-A10A-01 | TCGA-E2-A10A-01 | FEMALE | 41.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 40.38 | Luminal B | -3.0 | 0.0 | 1.0 | 2.0 | LumA/B | 2.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
424 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A0C0-01 | TCGA-BH-A0C0-01 | FEMALE | 62.0 | Positive | Positive | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | followup | LIVING | 41.73 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | Basal | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
425 | ER+ | ER+ | ER+ | TCGA-E2-A109-01 | TCGA-E2-A109-01 | FEMALE | 64.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 46.56 | Luminal B | -5.0 | -10.0 | 6.0 | 3.0 | LumA/B | 5.0 | 4.0 | 4.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
426 | ER+ | ER+ | ER+ | TCGA-AO-A0JC-01 | TCGA-AO-A0JC-01 | FEMALE | 64.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 50.83 | Luminal B | -5.0 | -2.0 | 2.0 | 5.0 | LumA | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
427 | ER+ | ER+ | ER+ | TCGA-BH-A0HW-01 | TCGA-BH-A0HW-01 | FEMALE | 62.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 51.25 | Luminal B | -3.0 | -10.0 | 2.0 | 2.0 | LumA/B | 4.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
428 | ER+ | ER+ | ER+ | TCGA-AO-A0JD-01 | TCGA-AO-A0JD-01 | FEMALE | 59.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 59.57 | Luminal B | -2.0 | -2.0 | 5.0 | 2.0 | Basal | 2.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
429 | HER2+ | ER+ | ER+/HER2+ | TCGA-AO-A0JM-01 | TCGA-AO-A0JM-01 | FEMALE | 40.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 59.99 | Luminal B | -5.0 | -2.0 | 5.0 | 3.0 | ReacII | 3.0 | 4.0 | 4.0 | 5.0 | Breast Cancer | Invasive Breast Carcinoma |
430 | ER+ | ER+ | ER+ | TCGA-A2-A0CW-01 | TCGA-A2-A0CW-01 | FEMALE | 67.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 63.97 | Luminal B | -5.0 | -2.0 | NaN | 1.0 | LumA/B | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
431 | ER+ | ER+ | ER+ | TCGA-A2-A0ER-01 | TCGA-A2-A0ER-01 | FEMALE | 63.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IB | No_Conversion | followup | LIVING | 74.32 | Luminal B | -3.0 | -10.0 | 2.0 | 2.0 | ReacII | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
432 | ER+ | ER+ | ER+ | TCGA-A2-A0CT-01 | TCGA-A2-A0CT-01 | FEMALE | 71.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 75.17 | Luminal B | -3.0 | -10.0 | 2.0 | 3.0 | LumA/B | 5.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
433 | ER+ | ER+ | ER+ | TCGA-AO-A12B-01 | TCGA-AO-A12B-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 77.50 | Luminal B | -3.0 | -12.0 | 3.0 | 2.0 | LumA/B | 3.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
434 | ER+ | ER+ | ER+ | TCGA-A2-A04R-01 | TCGA-A2-A04R-01 | FEMALE | 36.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 82.10 | Luminal B | -3.0 | -10.0 | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
435 | ER+ | ER+ | ER+ | TCGA-B6-A0IM-01 | TCGA-B6-A0IM-01 | FEMALE | 75.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 126.03 | Luminal B | -3.0 | -10.0 | 4.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
436 | ER+ | ER+ | ER+ | TCGA-AO-A03P-01 | TCGA-AO-A03P-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 84.63 | Luminal B | -5.0 | -10.0 | NaN | 2.0 | LumA/B | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
437 | HER2+ | ER+ | ER+/HER2+ | TCGA-A1-A0SM-01 | TCGA-A1-A0SM-01 | MALE | 77.0 | Positive | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 7.95 | Luminal B | -3.0 | -1.0 | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
438 | ER+ | ER+ | ER+ | TCGA-A8-A06N-01 | TCGA-A8-A06N-01 | FEMALE | 66.0 | Positive | Negative | Negative | T4 | T_Other | N0 | Negative | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 0.00 | Luminal B | -3.0 | -10.0 | 2.0 | 4.0 | LumA/B | 3.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
439 | ER+ | ER+ | ER+ | TCGA-A8-A06O-01 | TCGA-A8-A06O-01 | FEMALE | 60.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 13.01 | Luminal B | -3.0 | -2.0 | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
440 | ER+ | ER+ | ER+ | TCGA-A8-A06Q-01 | TCGA-A8-A06Q-01 | FEMALE | 63.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | enrollment | LIVING | 1.02 | Luminal B | -3.0 | -2.0 | 7.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
441 | ER+ | ER+ | ER+ | TCGA-A8-A06R-01 | TCGA-A8-A06R-01 | FEMALE | 69.0 | Positive | Negative | Equivocal | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 17.94 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | ReacI | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
442 | ER+ | ER+ | ER+ | TCGA-A8-A06Z-01 | TCGA-A8-A06Z-01 | FEMALE | 84.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 1.02 | Luminal B | -3.0 | -10.0 | 1.0 | 5.0 | Her2 | 5.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
443 | ER+ | ER+ | ER+ | TCGA-A8-A079-01 | TCGA-A8-A079-01 | FEMALE | 69.0 | Positive | Positive | Negative | T4 | T_Other | N3 | Positive | M0 | Negative | Stage IIIB | Stage IIIC | enrollment | LIVING | 9.00 | Luminal B | -3.0 | -6.0 | 5.0 | 3.0 | LumA/B | 5.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
444 | ER+ | ER+ | ER+ | TCGA-A8-A07L-01 | TCGA-A8-A07L-01 | FEMALE | 58.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 16.99 | Luminal B | -3.0 | -10.0 | 5.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
445 | ER+ | ER+ | ER+ | TCGA-A8-A07S-01 | TCGA-A8-A07S-01 | FEMALE | 73.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 7.95 | Luminal B | -3.0 | -12.0 | 7.0 | 2.0 | LumA | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
446 | ER+ | ER+ | ER+ | TCGA-A8-A07W-01 | TCGA-A8-A07W-01 | FEMALE | 76.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M1 | Positive | Stage IV | Stage IV | enrollment | LIVING | 9.99 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | LumA/B | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
447 | ER+ | ER+ | ER+ | TCGA-A8-A07Z-01 | TCGA-A8-A07Z-01 | FEMALE | 85.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 28.03 | Luminal B | -3.0 | -12.0 | 2.0 | 2.0 | LumA | 3.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
448 | ER+ | ER+ | ER+ | TCGA-A8-A082-01 | TCGA-A8-A082-01 | FEMALE | 58.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 18.04 | Luminal B | -3.0 | -9.0 | 5.0 | 4.0 | LumA | 4.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
449 | ER+ | ER+ | ER+ | TCGA-A8-A084-01 | TCGA-A8-A084-01 | FEMALE | 81.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 15.05 | Luminal B | -5.0 | -1.0 | 3.0 | 3.0 | X | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
450 | ER+ | ER+ | ER+ | TCGA-A8-A085-01 | TCGA-A8-A085-01 | MALE | 44.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 36.93 | Luminal B | -3.0 | -10.0 | 2.0 | 4.0 | LumA/B | 5.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
451 | ER+ | ER+ | ER+ | TCGA-A8-A08F-01 | TCGA-A8-A08F-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 18.04 | Luminal B | -3.0 | -2.0 | NaN | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
452 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A08G-01 | TCGA-A8-A08G-01 | FEMALE | 41.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.91 | Luminal B | -3.0 | -10.0 | 4.0 | 2.0 | LumA/B | 3.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
453 | ER+ | ER+ | ER+ | TCGA-A8-A08I-01 | TCGA-A8-A08I-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 11.99 | Luminal B | -5.0 | -2.0 | 3.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
454 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A08P-01 | TCGA-A8-A08P-01 | FEMALE | 70.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 30.95 | Luminal B | -5.0 | -2.0 | NaN | 4.0 | ReacII | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
455 | ER+ | ER+ | ER+ | TCGA-A8-A095-01 | TCGA-A8-A095-01 | FEMALE | 45.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 41.92 | Luminal B | -3.0 | -7.0 | 4.0 | 4.0 | ReacII | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
456 | ER+ | ER+ | ER+ | TCGA-A8-A096-01 | TCGA-A8-A096-01 | FEMALE | 73.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Luminal B | -4.0 | -12.0 | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
457 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A097-01 | TCGA-A8-A097-01 | FEMALE | 65.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 11.99 | Luminal B | -2.0 | 0.0 | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
458 | ER+ | ER+ | ER+ | TCGA-A8-A09C-01 | TCGA-A8-A09C-01 | FEMALE | 69.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage X | Stage IIA | enrollment | LIVING | 1.02 | Luminal B | -3.0 | 0.0 | 2.0 | 2.0 | LumA | 4.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
459 | ER+ | ER+ | ER+ | TCGA-A8-A09D-01 | TCGA-A8-A09D-01 | FEMALE | 47.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 13.01 | Luminal B | -3.0 | -3.0 | 1.0 | 1.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
460 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A09I-01 | TCGA-A8-A09I-01 | FEMALE | 84.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 33.05 | Luminal B | -5.0 | -2.0 | 4.0 | 3.0 | Her2 | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
461 | ER+ | ER+ | ER+ | TCGA-A8-A09M-01 | TCGA-A8-A09M-01 | FEMALE | 75.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 15.01 | Luminal B | -5.0 | -2.0 | 5.0 | 4.0 | LumA/B | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
462 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A09N-01 | TCGA-A8-A09N-01 | FEMALE | 57.0 | Positive | Positive | Positive | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 1.02 | Luminal B | -3.0 | 0.0 | 7.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
463 | ER+ | ER+ | ER+ | TCGA-A8-A09Q-01 | TCGA-A8-A09Q-01 | FEMALE | 83.0 | Positive | Positive | Negative | T4 | T_Other | N2 | Positive | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 25.00 | Luminal B | -5.0 | -2.0 | 4.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
464 | ER+ | ER+ | ER+ | TCGA-A8-A09R-01 | TCGA-A8-A09R-01 | FEMALE | 82.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 8.97 | Luminal B | -3.0 | 0.0 | 4.0 | 4.0 | Her2 | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
465 | ER+ | ER+ | ER+ | TCGA-A8-A09W-01 | TCGA-A8-A09W-01 | FEMALE | 70.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIB | Stage IIIC | enrollment | LIVING | 0.99 | Luminal B | -5.0 | -2.0 | NaN | 4.0 | Her2 | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
466 | ER+ | ER+ | ER+ | TCGA-A8-A09Z-01 | TCGA-A8-A09Z-01 | FEMALE | 83.0 | Positive | Negative | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | Luminal B | -5.0 | 0.0 | 2.0 | 4.0 | Basal | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
467 | ER+ | ER+ | ER+ | TCGA-A8-A0A9-01 | TCGA-A8-A0A9-01 | FEMALE | 80.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 13.01 | Luminal B | -3.0 | 0.0 | 2.0 | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
468 | ER+ | ER+ | ER+ | TCGA-A8-A0AB-01 | TCGA-A8-A0AB-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 16.99 | Luminal B | -3.0 | -1.0 | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
469 | ER+ | ER+ | ER+ | TCGA-AN-A03Y-01 | TCGA-AN-A03Y-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.33 | Luminal B | -3.0 | -1.0 | 5.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
470 | ER+ | ER+ | ER+ | TCGA-AN-A041-01 | TCGA-AN-A041-01 | FEMALE | 29.0 | Positive | Negative | Equivocal | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.23 | Luminal B | -3.0 | -2.0 | 4.0 | 4.0 | LumA | 5.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
471 | ER+ | ER+ | ER+ | TCGA-AN-A049-01 | TCGA-AN-A049-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.62 | Luminal B | -3.0 | 0.0 | 3.0 | 4.0 | ReacI | 5.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
472 | HER2+ | ER+ | ER+/HER2+ | TCGA-AN-A0AJ-01 | TCGA-AN-A0AJ-01 | FEMALE | 79.0 | Positive | Positive | Positive | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 7.98 | Luminal B | -5.0 | -2.0 | 4.0 | 3.0 | LumA | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
473 | ER+ | ER+ | ER+ | TCGA-AN-A0AK-01 | TCGA-AN-A0AK-01 | FEMALE | 76.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 7.33 | Luminal B | -5.0 | -10.0 | 1.0 | 4.0 | Basal | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
474 | ER+ | ER+ | ER+ | TCGA-AN-A0AM-01 | TCGA-AN-A0AM-01 | FEMALE | 56.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 0.16 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | LumA/B | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
475 | ER+ | ER+ | ER+ | TCGA-AN-A0AS-01 | TCGA-AN-A0AS-01 | FEMALE | 70.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | enrollment | LIVING | 0.30 | Luminal B | -3.0 | -1.0 | 2.0 | 2.0 | Basal | 3.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
476 | ER+ | ER+ | ER+ | TCGA-AN-A0FF-01 | TCGA-AN-A0FF-01 | FEMALE | 32.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | No_Conversion | enrollment | LIVING | 4.60 | Luminal B | -3.0 | 0.0 | 1.0 | 4.0 | LumA | 3.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
477 | ER+ | ER+ | ER+ | TCGA-AN-A0FK-01 | TCGA-AN-A0FK-01 | FEMALE | 88.0 | Positive | Positive | Negative | T4 | T_Other | N0 | Negative | M0 | Negative | Stage IIIB | No_Conversion | enrollment | LIVING | 6.97 | Luminal B | -3.0 | -12.0 | 4.0 | 2.0 | LumA | 2.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
478 | ER+ | ER+ | ER+ | TCGA-AN-A0FY-01 | TCGA-AN-A0FY-01 | FEMALE | 55.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IB | No_Conversion | enrollment | LIVING | 0.33 | Luminal B | -3.0 | -2.0 | 5.0 | 2.0 | LumA | 3.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
479 | ER+ | ER+ | ER+ | TCGA-AN-A0XR-01 | TCGA-AN-A0XR-01 | FEMALE | 55.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.33 | Luminal B | -3.0 | -12.0 | 4.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
480 | ER+ | ER+ | ER+ | TCGA-AN-A0XW-01 | TCGA-AN-A0XW-01 | FEMALE | 36.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 5.59 | Luminal B | -4.0 | -2.0 | 4.0 | 2.0 | Her2 | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
481 | HER2+ | ER+ | ER+/HER2+ | TCGA-AR-A0TQ-01 | TCGA-AR-A0TQ-01 | FEMALE | 27.0 | Positive | Negative | Positive | T3 | T_Other | N1 | Positive | M0 | Negative | Stage III | No_Conversion | enrollment | LIVING | 49.28 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | Her2 | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
482 | ER+ | ER+ | ER+ | TCGA-AR-A0TT-01 | TCGA-AR-A0TT-01 | FEMALE | 53.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | No_Conversion | enrollment | LIVING | 55.16 | Luminal B | -5.0 | -2.0 | 4.0 | 1.0 | LumA/B | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
483 | ER+ | ER+ | ER+ | TCGA-AR-A0TV-01 | TCGA-AR-A0TV-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 29.70 | Luminal B | -5.0 | -10.0 | 2.0 | 4.0 | LumA/B | 1.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
484 | ER+ | ER+ | ER+ | TCGA-AR-A0TZ-01 | TCGA-AR-A0TZ-01 | FEMALE | 43.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | No_Conversion | enrollment | LIVING | 43.14 | Luminal B | -3.0 | -10.0 | 2.0 | 3.0 | ReacII | 5.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
485 | ER+ | ER+ | ER+ | TCGA-AR-A0U3-01 | TCGA-AR-A0U3-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | No_Conversion | enrollment | LIVING | 74.35 | Luminal B | -3.0 | 0.0 | 7.0 | 3.0 | LumA/B | 4.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
486 | ER+ | ER+ | ER+ | TCGA-AR-A1AV-01 | TCGA-AR-A1AV-01 | MALE | 68.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 42.55 | Luminal B | -5.0 | -2.0 | 7.0 | 3.0 | LumA/B | 3.0 | 4.0 | 4.0 | 5.0 | Breast Cancer | Invasive Breast Carcinoma |
487 | ER+ | ER+ | ER+ | TCGA-BH-A0AU-01 | TCGA-BH-A0AU-01 | FEMALE | 45.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 24.51 | Luminal B | -3.0 | -3.0 | 6.0 | 2.0 | ReacI | 1.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
488 | ER+ | ER+ | ER+ | TCGA-BH-A0B5-01 | TCGA-BH-A0B5-01 | FEMALE | 40.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 48.33 | Luminal B | -3.0 | -7.0 | 7.0 | 4.0 | ReacII | 2.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
489 | ER+ | ER+ | ER+ | TCGA-BH-A0BF-01 | TCGA-BH-A0BF-01 | FEMALE | 56.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 25.66 | Luminal B | -5.0 | -2.0 | 4.0 | 1.0 | Basal | 2.0 | 4.0 | 3.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
490 | ER+ | ER+ | ER+ | TCGA-BH-A0BZ-01 | TCGA-BH-A0BZ-01 | FEMALE | 59.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 49.02 | Luminal B | -5.0 | -2.0 | 6.0 | 4.0 | X | 4.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
491 | ER+ | ER+ | ER+ | TCGA-BH-A0C3-01 | TCGA-BH-A0C3-01 | FEMALE | 47.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 48.10 | Luminal B | 0.0 | -4.0 | 6.0 | 2.0 | Her2 | 3.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
492 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A0C7-01 | TCGA-BH-A0C7-01 | FEMALE | 48.0 | Positive | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 42.88 | Luminal B | -3.0 | 0.0 | 4.0 | 4.0 | LumA/B | 5.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
493 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A0DD-01 | TCGA-BH-A0DD-01 | MALE | 58.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 45.77 | Luminal B | -3.0 | -6.0 | 4.0 | 4.0 | LumA/B | 3.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
494 | ER+ | ER+ | ER+ | TCGA-BH-A0W3-01 | TCGA-BH-A0W3-01 | FEMALE | 58.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | No_Conversion | enrollment | LIVING | 5.91 | Luminal B | -3.0 | -12.0 | 5.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
495 | ER+ | ER+ | ER+ | TCGA-BH-A18F-01 | TCGA-BH-A18F-01 | FEMALE | 50.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 8.81 | Luminal B | -7.0 | -4.0 | 6.0 | 1.0 | ReacI | 2.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
496 | ER+ | ER+ | ER+ | TCGA-C8-A12M-01 | TCGA-C8-A12M-01 | FEMALE | 70.0 | Positive | Negative | Not Available | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Luminal B | -5.0 | -10.0 | 4.0 | 3.0 | LumA/B | 5.0 | 4.0 | 4.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
497 | ER+ | ER+ | ER+ | TCGA-C8-A12U-01 | TCGA-C8-A12U-01 | FEMALE | 46.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IB | Stage IIB | enrollment | LIVING | 0.00 | Luminal B | -5.0 | -2.0 | 5.0 | 4.0 | Basal | 5.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
498 | ER+ | ER+ | ER+ | TCGA-C8-A12W-01 | TCGA-C8-A12W-01 | FEMALE | 49.0 | Positive | Positive | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 0.00 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | ReacII | 3.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
499 | ER+ | ER+ | ER+ | TCGA-C8-A12X-01 | TCGA-C8-A12X-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | Luminal B | -3.0 | -10.0 | 1.0 | 3.0 | LumA/B | 4.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
500 | ER+ | ER+ | ER+ | TCGA-C8-A1HG-01 | TCGA-C8-A1HG-01 | FEMALE | 50.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | Luminal B | -5.0 | -2.0 | 3.0 | 5.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
501 | HER2+ | ER+ | ER+/HER2+ | TCGA-C8-A1HL-01 | TCGA-C8-A1HL-01 | FEMALE | 38.0 | Positive | Negative | Positive | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.07 | Luminal B | -3.0 | -2.0 | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
502 | ER+ | ER+ | ER+ | TCGA-C8-A1HM-01 | TCGA-C8-A1HM-01 | FEMALE | 74.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 0.20 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
503 | ER+ | ER+ | ER+ | TCGA-C8-A1HN-01 | TCGA-C8-A1HN-01 | FEMALE | 56.0 | Positive | Positive | Equivocal | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 0.07 | Luminal B | -5.0 | -10.0 | 7.0 | 2.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
504 | ER+ | ER+ | ER+ | TCGA-E2-A14O-01 | TCGA-E2-A14O-01 | FEMALE | 76.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 38.51 | Luminal B | -3.0 | 0.0 | 4.0 | 4.0 | LumA/B | 2.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
505 | ER+ | ER+ | ER+ | TCGA-E2-A14S-01 | TCGA-E2-A14S-01 | FEMALE | 65.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 27.40 | Luminal B | -3.0 | -10.0 | 2.0 | 4.0 | LumA/B | 4.0 | 4.0 | 1.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
506 | HER2+ | ER+ | ER+/HER2+ | TCGA-E2-A14W-01 | TCGA-E2-A14W-01 | FEMALE | 78.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 27.37 | Luminal B | -3.0 | 0.0 | 7.0 | 2.0 | Her2 | 5.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
507 | ER+ | ER+ | ER+ | TCGA-E2-A155-01 | TCGA-E2-A155-01 | FEMALE | 58.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 18.17 | Luminal B | -3.0 | -10.0 | 5.0 | 3.0 | LumA/B | 1.0 | 4.0 | 4.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
508 | ER+ | ER+ | ER+ | TCGA-E2-A15A-01 | TCGA-E2-A15A-01 | FEMALE | 45.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 16.49 | Luminal B | -5.0 | -2.0 | 4.0 | 4.0 | Her2 | 4.0 | 4.0 | 1.0 | 1.0 | Breast Cancer | Invasive Breast Carcinoma |
509 | ER+ | ER+ | ER+ | TCGA-E2-A15K-01 | TCGA-E2-A15K-01 | FEMALE | 58.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | Stage IIB | enrollment | LIVING | 1.12 | Luminal B | -3.0 | -12.0 | 4.0 | 2.0 | LumA | 2.0 | 4.0 | 3.0 | 3.0 | Breast Cancer | Invasive Breast Carcinoma |
510 | ER+ | ER+ | ER+ | TCGA-E2-A15L-01 | TCGA-E2-A15L-01 | FEMALE | 65.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 10.87 | Luminal B | -3.0 | -12.0 | NaN | 2.0 | ReacI | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
511 | ER+ | ER+ | ER+ | TCGA-E2-A15M-01 | TCGA-E2-A15M-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 7.69 | Luminal B | -4.0 | -4.0 | 6.0 | 1.0 | ReacI | 3.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
512 | ER+ | ER+ | ER+ | TCGA-E2-A15S-01 | TCGA-E2-A15S-01 | FEMALE | 34.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 9.00 | Luminal B | -3.0 | -10.0 | 6.0 | 4.0 | LumA/B | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
513 | ER+ | ER+ | ER+ | TCGA-E2-A15T-01 | TCGA-E2-A15T-01 | FEMALE | 65.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 8.77 | Luminal B | -3.0 | -10.0 | 2.0 | 4.0 | LumA/B | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
514 | TNBC | TNBC | TNBC | TCGA-AO-A03U-01 | TCGA-AO-A03U-01 | FEMALE | 31.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | DECEASED | 59.01 | Normal-like | 0.0 | -5.0 | 4.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
515 | TNBC | TNBC | TNBC | TCGA-B6-A0IE-01 | TCGA-B6-A0IE-01 | FEMALE | 38.0 | Negative | Negative | Negative | TX | NaN | N1 | Positive | M0 | Negative | NaN | No_Conversion | followup | DECEASED | 65.64 | Normal-like | -3.0 | -2.0 | 4.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
516 | ER+ | ER+ | ER+ | TCGA-A2-A0YK-01 | TCGA-A2-A0YK-01 | FEMALE | 61.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 19.29 | Normal-like | -7.0 | -5.0 | 6.0 | 1.0 | ReacII | 5.0 | 3.0 | 3.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
517 | ER+ | ER+ | ER+ | TCGA-E2-A108-01 | TCGA-E2-A108-01 | FEMALE | 64.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 27.50 | Normal-like | -8.0 | -5.0 | 4.0 | 1.0 | ReacI | 4.0 | 3.0 | 1.0 | 4.0 | Breast Cancer | Invasive Breast Carcinoma |
518 | ER+ | ER+ | ER+ | TCGA-AO-A0JB-01 | TCGA-AO-A0JB-01 | FEMALE | 50.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | No_Conversion | followup | LIVING | 37.78 | Normal-like | -3.0 | -2.0 | 2.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
519 | ER+ | ER+ | ER+ | TCGA-AO-A03R-01 | TCGA-AO-A03R-01 | FEMALE | 57.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | followup | LIVING | 56.08 | Normal-like | 0.0 | 0.0 | 2.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
520 | ER+ | ER+ | ER+ | TCGA-AO-A03T-01 | TCGA-AO-A03T-01 | FEMALE | 42.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | No_Conversion | enrollment | LIVING | 39.00 | Normal-like | -3.0 | -2.0 | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
521 | ER+ | ER+ | ER+ | TCGA-AR-A1AO-01 | TCGA-AR-A1AO-01 | FEMALE | 47.0 | Positive | Negative | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 43.50 | Normal-like | -8.0 | -5.0 | 4.0 | 5.0 | Basal | 1.0 | 2.0 | 2.0 | 2.0 | Breast Cancer | Invasive Breast Carcinoma |
522 | ER+ | ER+ | ER+ | TCGA-A2-A0YT-01 | TCGA-A2-A0YT-01 | FEMALE | 56.0 | Positive | Negative | Negative | T4 | T_Other | N2 | Positive | M0 | Negative | Stage IIIB | No_Conversion | followup | DECEASED | 23.75 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
523 | HER2+ | ER+ | ER+/HER2+ | TCGA-AQ-A0Y5-01 | TCGA-AQ-A0Y5-01 | FEMALE | 70.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | followup | DECEASED | 5.29 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
524 | TNBC | TNBC | TNBC | TCGA-EW-A1P8-01 | TCGA-EW-A1P8-01 | FEMALE | 58.0 | Negative | Negative | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | DECEASED | 7.85 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
525 | TNBC | TNBC | TNBC | TCGA-E2-A1LK-01 | TCGA-E2-A1LK-01 | FEMALE | 84.0 | Negative | Negative | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIC | Stage IIIA | enrollment | DECEASED | 8.74 | NaN | NaN | NaN | 5.0 | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
526 | ER+ | ER+ | ER+ | TCGA-BH-A1EY-01 | TCGA-BH-A1EY-01 | FEMALE | 79.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 17.68 | NaN | NaN | NaN | 1.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
527 | ER+ | ER+ | ER+ | TCGA-BH-A1F8-01 | TCGA-BH-A1F8-01 | FEMALE | 90.0 | Positive | Positive | Negative | T4 | T_Other | N2 | Positive | M0 | Negative | Stage IIIB | Stage IIIC | enrollment | DECEASED | 24.61 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
528 | HER2+ | ER+ | ER+/HER2+ | TCGA-BH-A1F2-01 | TCGA-BH-A1F2-01 | FEMALE | 53.0 | Positive | Positive | Positive | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage | enrollment | DECEASED | 31.51 | NaN | NaN | NaN | 6.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
529 | ER+ | ER+ | ER+ | TCGA-BH-A1FD-01 | TCGA-BH-A1FD-01 | FEMALE | 68.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | DECEASED | 33.12 | NaN | NaN | NaN | NaN | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
530 | ER+ | ER+ | ER+ | TCGA-BH-A1FH-01 | TCGA-BH-A1FH-01 | FEMALE | 47.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M1 | Positive | Stage IV | No_Conversion | enrollment | DECEASED | 36.90 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
531 | NaN | NaN | NaN | TCGA-BH-A203-01 | TCGA-BH-A203-01 | FEMALE | 78.0 | Performed but Not Available | Performed but Not Available | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 38.57 | NaN | NaN | NaN | NaN | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
532 | ER+ | ER+ | ER+ | TCGA-BH-A1FM-01 | TCGA-BH-A1FM-01 | FEMALE | 44.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | DECEASED | 45.60 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
533 | ER+ | ER+ | ER+ | TCGA-BH-A1EX-01 | TCGA-BH-A1EX-01 | FEMALE | 67.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | DECEASED | 49.55 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
534 | ER+ | ER+ | ER+ | TCGA-BH-A1FL-01 | TCGA-BH-A1FL-01 | FEMALE | 69.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIIA | enrollment | DECEASED | 54.97 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
535 | NaN | NaN | NaN | TCGA-BH-A208-01 | TCGA-BH-A208-01 | FEMALE | 48.0 | Performed but Not Available | Performed but Not Available | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 57.79 | NaN | NaN | NaN | NaN | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
536 | ER+ | ER+ | ER+ | TCGA-GM-A2D9-01 | TCGA-GM-A2D9-01 | FEMALE | 69.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 59.53 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
537 | NaN | NaN | NaN | TCGA-BH-A1FJ-01 | TCGA-BH-A1FJ-01 | FEMALE | 66.0 | Negative | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | DECEASED | 63.31 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
538 | HER2+ | HER2+ | ER-/HER2+ | TCGA-BH-A1EN-01 | TCGA-BH-A1EN-01 | FEMALE | 78.0 | Negative | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 67.42 | NaN | NaN | NaN | 3.0 | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
539 | ER+ | ER+ | ER+ | TCGA-BH-A1FN-01 | TCGA-BH-A1FN-01 | FEMALE | 34.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 72.02 | NaN | NaN | NaN | 4.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
540 | HER2+ | HER2+ | ER-/HER2+ | TCGA-BH-A1FU-01 | TCGA-BH-A1FU-01 | FEMALE | 44.0 | Negative | Negative | Positive | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | DECEASED | 72.02 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
541 | ER+ | ER+ | ER+ | TCGA-BH-A1FE-01 | TCGA-BH-A1FE-01 | FEMALE | 31.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | DECEASED | 74.68 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
542 | NaN | NaN | NaN | TCGA-BH-A204-01 | TCGA-BH-A204-01 | FEMALE | 80.0 | Performed but Not Available | Performed but Not Available | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 83.25 | NaN | NaN | NaN | NaN | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
543 | ER+ | ER+ | ER+ | TCGA-BH-A1F5-01 | TCGA-BH-A1F5-01 | FEMALE | 62.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 89.10 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
544 | TNBC | TNBC | TNBC | TCGA-AR-A256-01 | TCGA-AR-A256-01 | FEMALE | 45.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | DECEASED | 93.77 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
545 | NaN | NaN | NaN | TCGA-BH-A1F6-01 | TCGA-BH-A1F6-01 | FEMALE | 51.0 | Negative | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 97.41 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
546 | TNBC | TNBC | TNBC | TCGA-BH-A1FC-01 | TCGA-BH-A1FC-01 | FEMALE | 78.0 | Negative | Negative | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | DECEASED | 114.04 | NaN | NaN | NaN | 3.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
547 | ER+ | ER+ | ER+ | TCGA-BH-A1FB-01 | TCGA-BH-A1FB-01 | FEMALE | 60.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | DECEASED | 120.54 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
548 | ER+ | ER+ | ER+ | TCGA-BH-A1FG-01 | TCGA-BH-A1FG-01 | FEMALE | 88.0 | Positive | Positive | Not Available | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | DECEASED | 122.81 | NaN | NaN | NaN | 2.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
549 | ER+ | ER+ | ER+ | TCGA-BH-A209-01 | TCGA-BH-A209-01 | FEMALE | 77.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | DECEASED | 130.07 | NaN | NaN | NaN | NaN | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
550 | ER+ | ER+ | ER+ | TCGA-BH-A1FR-01 | TCGA-BH-A1FR-01 | FEMALE | 73.0 | Positive | Positive | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | No_Conversion | enrollment | DECEASED | 144.50 | NaN | NaN | NaN | 1.0 | 2.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
551 | ER+ | ER+ | ER+ | TCGA-AO-A1KS-01 | TCGA-AO-A1KS-01 | FEMALE | 69.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 0.53 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
552 | ER+ | ER+ | ER+ | TCGA-A7-A13G-01 | TCGA-A7-A13G-01 | FEMALE | 79.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 11.43 | NaN | NaN | NaN | 3.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
553 | ER+ | ER+ | ER+ | TCGA-D8-A1JS-01 | TCGA-D8-A1JS-01 | FEMALE | 77.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 12.19 | NaN | NaN | NaN | 3.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
554 | ER+ | ER+ | ER+ | TCGA-A7-A0DC-01 | TCGA-A7-A0DC-01 | FEMALE | 63.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 12.68 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
555 | ER+ | ER+ | ER+ | TCGA-D8-A1JT-01 | TCGA-D8-A1JT-01 | FEMALE | 70.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 13.31 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
556 | ER+ | ER+ | ER+ | TCGA-A7-A26E-01 | TCGA-A7-A26E-01 | FEMALE | 71.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | followup | LIVING | 13.83 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
557 | ER+ | ER+ | ER+ | TCGA-D8-A1JH-01 | TCGA-D8-A1JH-01 | FEMALE | 56.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 14.00 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
558 | ER+ | ER+ | ER+ | TCGA-D8-A1JU-01 | TCGA-D8-A1JU-01 | FEMALE | 51.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | followup | LIVING | 14.69 | NaN | NaN | NaN | 6.0 | 5.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
559 | ER+ | ER+ | ER+ | TCGA-AO-A1KO-01 | TCGA-AO-A1KO-01 | FEMALE | 46.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 14.72 | NaN | NaN | NaN | 6.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
560 | ER+ | ER+ | ER+ | TCGA-AO-A1KT-01 | TCGA-AO-A1KT-01 | FEMALE | 78.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 17.77 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
561 | ER+ | ER+ | ER+ | TCGA-AO-A0J5-01 | TCGA-AO-A0J5-01 | FEMALE | 48.0 | Positive | Negative | Negative | T4 | T_Other | N1 | Positive | M1 | Positive | Stage IV | No_Conversion | followup | LIVING | 23.13 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
562 | ER+ | ER+ | ER+ | TCGA-B6-A1KC-01 | TCGA-B6-A1KC-01 | FEMALE | 67.0 | Positive | Negative | Not Available | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | Stage IIB | followup | LIVING | 43.57 | NaN | NaN | NaN | 5.0 | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
563 | ER+ | ER+ | ER+ | TCGA-AO-A1KQ-01 | TCGA-AO-A1KQ-01 | MALE | 84.0 | Positive | Positive | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage IIIB | followup | LIVING | 49.91 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
564 | ER+ | ER+ | ER+ | TCGA-B6-A1KI-01 | TCGA-B6-A1KI-01 | FEMALE | 63.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | followup | LIVING | 73.46 | NaN | NaN | NaN | 2.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
565 | ER+ | ER+ | ER+ | TCGA-AO-A1KP-01 | TCGA-AO-A1KP-01 | FEMALE | 77.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | followup | LIVING | 82.56 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
566 | HER2+ | HER2+ | ER-/HER2+ | TCGA-B6-A1KF-01 | TCGA-B6-A1KF-01 | FEMALE | 68.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | followup | LIVING | 101.46 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
567 | HER2+ | HER2+ | ER-/HER2+ | TCGA-B6-A1KN-01 | TCGA-B6-A1KN-01 | FEMALE | 57.0 | Negative | Negative | Positive | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage IIIC | followup | LIVING | 139.08 | NaN | NaN | NaN | 6.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
568 | ER+ | ER+ | ER+ | TCGA-D8-A1XO-01 | TCGA-D8-A1XO-01 | FEMALE | 56.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 7.95 | NaN | NaN | NaN | 7.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
569 | HER2+ | HER2+ | ER-/HER2+ | TCGA-D8-A1XT-01 | TCGA-D8-A1XT-01 | FEMALE | 61.0 | Negative | Negative | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 6.34 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
570 | TNBC | TNBC | TNBC | TCGA-A1-A0SP-01 | TCGA-A1-A0SP-01 | FEMALE | 40.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.15 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
571 | ER+ | ER+ | ER+ | TCGA-D8-A1J8-01 | TCGA-D8-A1J8-01 | FEMALE | 77.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 8.41 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
572 | TNBC | TNBC | TNBC | TCGA-D8-A1JF-01 | TCGA-D8-A1JF-01 | FEMALE | 79.0 | Negative | Negative | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 3.15 | NaN | NaN | NaN | 3.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
573 | TNBC | TNBC | TNBC | TCGA-D8-A1JG-01 | TCGA-D8-A1JG-01 | FEMALE | 62.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 6.14 | NaN | NaN | NaN | 3.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
574 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A1XS-01 | TCGA-D8-A1XS-01 | MALE | 48.0 | Positive | Positive | Positive | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 0.59 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
575 | ER+ | ER+ | ER+ | TCGA-A1-A0SB-01 | TCGA-A1-A0SB-01 | FEMALE | 70.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 8.51 | NaN | NaN | NaN | 3.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
576 | ER+ | ER+ | ER+ | TCGA-A1-A0SF-01 | TCGA-A1-A0SF-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 48.07 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
577 | ER+ | ER+ | ER+ | TCGA-A1-A0SG-01 | TCGA-A1-A0SG-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 14.23 | NaN | NaN | NaN | 5.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
578 | ER+ | ER+ | ER+ | TCGA-A1-A0SI-01 | TCGA-A1-A0SI-01 | FEMALE | 52.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 20.83 | NaN | NaN | NaN | 7.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
579 | HER2+ | ER+ | ER+/HER2+ | TCGA-A1-A0SN-01 | TCGA-A1-A0SN-01 | FEMALE | 50.0 | Positive | Positive | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIA | enrollment | LIVING | 39.29 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
580 | ER+ | ER+ | ER+ | TCGA-A1-A0SQ-01 | TCGA-A1-A0SQ-01 | FEMALE | 45.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 18.17 | NaN | NaN | NaN | 2.0 | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
581 | ER+ | ER+ | ER+ | TCGA-A2-A1FV-01 | TCGA-A2-A1FV-01 | FEMALE | 74.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 15.11 | NaN | NaN | NaN | 6.0 | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
582 | ER+ | ER+ | ER+ | TCGA-A2-A1FW-01 | TCGA-A2-A1FW-01 | FEMALE | 62.0 | Positive | Negative | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 7.26 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
583 | ER+ | ER+ | ER+ | TCGA-A2-A1FX-01 | TCGA-A2-A1FX-01 | FEMALE | 61.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 30.72 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
584 | ER+ | ER+ | ER+ | TCGA-A2-A1FZ-01 | TCGA-A2-A1FZ-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 13.44 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
585 | ER+ | ER+ | ER+ | TCGA-A2-A1G0-01 | TCGA-A2-A1G0-01 | FEMALE | 49.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 12.48 | NaN | NaN | NaN | 6.0 | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
586 | HER2+ | HER2+ | ER-/HER2+ | TCGA-A2-A1G1-01 | TCGA-A2-A1G1-01 | FEMALE | 85.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 12.19 | NaN | NaN | NaN | 6.0 | 5.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
587 | ER+ | ER+ | ER+ | TCGA-A2-A1G4-01 | TCGA-A2-A1G4-01 | FEMALE | 71.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 12.22 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
588 | TNBC | TNBC | TNBC | TCGA-A2-A1G6-01 | TCGA-A2-A1G6-01 | FEMALE | 50.0 | Negative | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 4.34 | NaN | NaN | NaN | 6.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
589 | ER+ | ER+ | ER+ | TCGA-A2-A259-01 | TCGA-A2-A259-01 | FEMALE | 70.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 42.22 | NaN | NaN | NaN | NaN | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
590 | ER+ | ER+ | ER+ | TCGA-A2-A25A-01 | TCGA-A2-A25A-01 | FEMALE | 44.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 97.51 | NaN | NaN | NaN | NaN | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
591 | ER+ | ER+ | ER+ | TCGA-A2-A25B-01 | TCGA-A2-A25B-01 | FEMALE | 39.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 8.48 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
592 | ER+ | ER+ | ER+ | TCGA-A2-A25C-01 | TCGA-A2-A25C-01 | FEMALE | 50.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 9.36 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
593 | ER+ | ER+ | ER+ | TCGA-A2-A25D-01 | TCGA-A2-A25D-01 | FEMALE | 90.0 | Positive | Negative | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 7.98 | NaN | NaN | NaN | NaN | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
594 | ER+ | ER+ | ER+ | TCGA-A2-A25E-01 | TCGA-A2-A25E-01 | FEMALE | 34.0 | Positive | Positive | Equivocal | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 82.50 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
595 | NaN | NaN | NaN | TCGA-A2-A25F-01 | TCGA-A2-A25F-01 | FEMALE | 66.0 | Negative | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 3.71 | NaN | NaN | NaN | NaN | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
596 | TNBC | TNBC | TNBC | TCGA-A7-A26F-01 | TCGA-A7-A26F-01 | FEMALE | 55.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 8.44 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
597 | TNBC | TNBC | TNBC | TCGA-A7-A26G-01 | TCGA-A7-A26G-01 | FEMALE | 50.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 6.87 | NaN | NaN | NaN | 4.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
598 | HER2+ | ER+ | ER+/HER2+ | TCGA-A7-A26H-01 | TCGA-A7-A26H-01 | FEMALE | 72.0 | Positive | Negative | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 2.10 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
599 | TNBC | TNBC | TNBC | TCGA-A7-A26I-01 | TCGA-A7-A26I-01 | FEMALE | 65.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 4.01 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
600 | ER+ | ER+ | ER+ | TCGA-A7-A26J-01 | TCGA-A7-A26J-01 | FEMALE | 49.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 2.20 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
601 | HER2+ | ER+ | ER+/HER2+ | TCGA-A8-A08S-01 | TCGA-A8-A08S-01 | FEMALE | 71.0 | Positive | Positive | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.06 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
602 | ER+ | ER+ | ER+ | TCGA-A8-A09E-01 | TCGA-A8-A09E-01 | FEMALE | 73.0 | Positive | Positive | Equivocal | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 30.95 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
603 | ER+ | ER+ | ER+ | TCGA-A8-A09K-01 | TCGA-A8-A09K-01 | FEMALE | 68.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 29.93 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
604 | HER2+ | ER+ | ER+/HER2+ | TCGA-AC-A23C-01 | TCGA-AC-A23C-01 | FEMALE | 62.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | NaN | Stage IIB | enrollment | LIVING | 0.95 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
605 | ER+ | ER+ | ER+ | TCGA-AC-A23E-01 | TCGA-AC-A23E-01 | FEMALE | 50.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | NaN | Stage IIB | enrollment | LIVING | 2.37 | NaN | NaN | NaN | NaN | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
606 | HER2+ | ER+ | ER+/HER2+ | TCGA-AC-A23H-01 | TCGA-AC-A23H-01 | FEMALE | 90.0 | Positive | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | NaN | Stage IIA | enrollment | LIVING | 2.66 | NaN | NaN | NaN | NaN | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
607 | NaN | NaN | NaN | TCGA-AO-A1KR-01 | TCGA-AO-A1KR-01 | FEMALE | 51.0 | Negative | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 70.31 | NaN | NaN | NaN | 3.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
608 | HER2+ | ER+ | ER+/HER2+ | TCGA-AQ-A1H2-01 | TCGA-AQ-A1H2-01 | FEMALE | 84.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 6.47 | NaN | NaN | NaN | 1.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
609 | ER+ | ER+ | ER+ | TCGA-AQ-A1H3-01 | TCGA-AQ-A1H3-01 | FEMALE | 49.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 4.53 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
610 | ER+ | ER+ | ER+ | TCGA-AR-A24H-01 | TCGA-AR-A24H-01 | FEMALE | 65.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 109.51 | NaN | NaN | NaN | NaN | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
611 | ER+ | ER+ | ER+ | TCGA-AR-A24K-01 | TCGA-AR-A24K-01 | FEMALE | 46.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 50.86 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
612 | ER+ | ER+ | ER+ | TCGA-AR-A24L-01 | TCGA-AR-A24L-01 | FEMALE | 26.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 72.97 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
613 | ER+ | ER+ | ER+ | TCGA-AR-A24M-01 | TCGA-AR-A24M-01 | FEMALE | 38.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 65.38 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
614 | ER+ | ER+ | ER+ | TCGA-AR-A24N-01 | TCGA-AR-A24N-01 | FEMALE | 54.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 68.14 | NaN | NaN | NaN | 3.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
615 | ER+ | ER+ | ER+ | TCGA-AR-A24O-01 | TCGA-AR-A24O-01 | FEMALE | 43.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 65.61 | NaN | NaN | NaN | 7.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
616 | ER+ | ER+ | ER+ | TCGA-AR-A24P-01 | TCGA-AR-A24P-01 | FEMALE | 47.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 0.85 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
617 | ER+ | ER+ | ER+ | TCGA-AR-A24Q-01 | TCGA-AR-A24Q-01 | FEMALE | 49.0 | Positive | Negative | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 65.97 | NaN | NaN | NaN | 6.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
618 | ER+ | ER+ | ER+ | TCGA-AR-A24R-01 | TCGA-AR-A24R-01 | FEMALE | 45.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 57.33 | NaN | NaN | NaN | 5.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
619 | ER+ | ER+ | ER+ | TCGA-AR-A24S-01 | TCGA-AR-A24S-01 | FEMALE | 61.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 62.03 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
620 | ER+ | ER+ | ER+ | TCGA-AR-A24T-01 | TCGA-AR-A24T-01 | FEMALE | 46.0 | Positive | Positive | Negative | T3 | T_Other | N3 | Positive | M0 | Negative | Stage III | Stage IIIC | enrollment | LIVING | 53.23 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
621 | HER2+ | HER2+ | ER-/HER2+ | TCGA-AR-A24U-01 | TCGA-AR-A24U-01 | FEMALE | 47.0 | Negative | Negative | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 53.32 | NaN | NaN | NaN | 7.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
622 | ER+ | ER+ | ER+ | TCGA-AR-A24V-01 | TCGA-AR-A24V-01 | FEMALE | 52.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 54.14 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
623 | ER+ | ER+ | ER+ | TCGA-AR-A24X-01 | TCGA-AR-A24X-01 | FEMALE | 52.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 48.13 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
624 | ER+ | ER+ | ER+ | TCGA-AR-A24Z-01 | TCGA-AR-A24Z-01 | FEMALE | 57.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 51.71 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
625 | HER2+ | ER+ | ER+/HER2+ | TCGA-AR-A250-01 | TCGA-AR-A250-01 | FEMALE | 58.0 | Positive | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 56.08 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
626 | ER+ | ER+ | ER+ | TCGA-AR-A251-01 | TCGA-AR-A251-01 | FEMALE | 51.0 | Positive | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 45.11 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
627 | ER+ | ER+ | ER+ | TCGA-AR-A252-01 | TCGA-AR-A252-01 | FEMALE | 50.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 40.61 | NaN | NaN | NaN | 1.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
628 | HER2+ | ER+ | ER+/HER2+ | TCGA-AR-A254-01 | TCGA-AR-A254-01 | FEMALE | 50.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 39.82 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
629 | HER2+ | ER+ | ER+/HER2+ | TCGA-AR-A255-01 | TCGA-AR-A255-01 | FEMALE | 62.0 | Positive | Positive | Positive | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 34.76 | NaN | NaN | NaN | NaN | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
630 | ER+ | ER+ | ER+ | TCGA-BH-A0B2-01 | TCGA-BH-A0B2-01 | FEMALE | 43.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 40.81 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
631 | ER+ | ER+ | ER+ | TCGA-BH-A0DV-01 | TCGA-BH-A0DV-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 45.14 | NaN | NaN | NaN | 6.0 | 1.0 | ReacII | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
632 | ER+ | ER+ | ER+ | TCGA-BH-A201-01 | TCGA-BH-A201-01 | FEMALE | 64.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 6.87 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
633 | ER+ | ER+ | ER+ | TCGA-BH-A202-01 | TCGA-BH-A202-01 | FEMALE | 60.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 0.72 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
634 | ER+ | ER+ | ER+ | TCGA-BH-A28Q-01 | TCGA-BH-A28Q-01 | FEMALE | 46.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 6.44 | NaN | NaN | NaN | NaN | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
635 | ER+ | ER+ | ER+ | TCGA-C8-A1HE-01 | TCGA-C8-A1HE-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
636 | TNBC | TNBC | TNBC | TCGA-C8-A1HJ-01 | TCGA-C8-A1HJ-01 | FEMALE | 53.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 0.16 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
637 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A1HK-01 | TCGA-C8-A1HK-01 | FEMALE | 53.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.23 | NaN | NaN | NaN | 1.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
638 | ER+ | ER+ | ER+ | TCGA-C8-A1HO-01 | TCGA-C8-A1HO-01 | FEMALE | 34.0 | Positive | Positive | Negative | T3 | T_Other | N3 | Positive | M0 | Negative | Stage III | Stage IIIC | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 5.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
639 | ER+ | ER+ | ER+ | TCGA-C8-A26V-01 | TCGA-C8-A26V-01 | FEMALE | 47.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage III | Stage IIIA | enrollment | LIVING | 0.30 | NaN | NaN | NaN | NaN | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
640 | HER2+ | ER+ | ER+/HER2+ | TCGA-C8-A26W-01 | TCGA-C8-A26W-01 | FEMALE | 58.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage II | Stage IIB | enrollment | LIVING | 0.23 | NaN | NaN | NaN | NaN | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
641 | TNBC | TNBC | TNBC | TCGA-C8-A26X-01 | TCGA-C8-A26X-01 | FEMALE | 58.0 | Negative | Negative | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 0.36 | NaN | NaN | NaN | NaN | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
642 | TNBC | TNBC | TNBC | TCGA-C8-A26Y-01 | TCGA-C8-A26Y-01 | FEMALE | 90.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage II | Stage IIA | enrollment | LIVING | 0.43 | NaN | NaN | NaN | NaN | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
643 | ER+ | ER+ | ER+ | TCGA-C8-A26Z-01 | TCGA-C8-A26Z-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.13 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
644 | ER+ | ER+ | ER+ | TCGA-C8-A273-01 | TCGA-C8-A273-01 | FEMALE | 29.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.20 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
645 | ER+ | ER+ | ER+ | TCGA-C8-A274-01 | TCGA-C8-A274-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.03 | NaN | NaN | NaN | NaN | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
646 | HER2+ | HER2+ | None | TCGA-C8-A275-01 | TCGA-C8-A275-01 | FEMALE | 56.0 | Not Performed | Not Performed | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.03 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
647 | HER2+ | HER2+ | ER-/HER2+ | TCGA-C8-A278-01 | TCGA-C8-A278-01 | FEMALE | 61.0 | Negative | Negative | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.03 | NaN | NaN | NaN | NaN | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
648 | ER+ | ER+ | ER+ | TCGA-C8-A27A-01 | TCGA-C8-A27A-01 | FEMALE | 48.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 12.19 | NaN | NaN | NaN | 5.0 | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
649 | TNBC | TNBC | TNBC | TCGA-C8-A27B-01 | TCGA-C8-A27B-01 | FEMALE | 48.0 | Negative | Negative | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.99 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
650 | ER+ | ER+ | ER+ | TCGA-D8-A146-01 | TCGA-D8-A146-01 | FEMALE | 57.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 11.30 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
651 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A1J9-01 | TCGA-D8-A1J9-01 | FEMALE | 48.0 | Positive | Negative | Positive | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 8.15 | NaN | NaN | NaN | 1.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
652 | HER2+ | HER2+ | ER-/HER2+ | TCGA-D8-A1JA-01 | TCGA-D8-A1JA-01 | FEMALE | 60.0 | Negative | Negative | Positive | T4 | T_Other | N0 | Negative | M0 | Negative | Stage X | Stage IIIB | enrollment | LIVING | 0.59 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
653 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A1JB-01 | TCGA-D8-A1JB-01 | FEMALE | 54.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
654 | ER+ | ER+ | ER+ | TCGA-D8-A1JC-01 | TCGA-D8-A1JC-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 5.85 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
655 | ER+ | ER+ | ER+ | TCGA-D8-A1JD-01 | TCGA-D8-A1JD-01 | FEMALE | 41.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 8.97 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
656 | ER+ | ER+ | ER+ | TCGA-D8-A1JE-01 | TCGA-D8-A1JE-01 | FEMALE | 62.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 1.87 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
657 | ER+ | ER+ | ER+ | TCGA-D8-A1JI-01 | TCGA-D8-A1JI-01 | FEMALE | 54.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.69 | NaN | NaN | NaN | 1.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
658 | ER+ | ER+ | ER+ | TCGA-D8-A1JJ-01 | TCGA-D8-A1JJ-01 | FEMALE | 54.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 9.00 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
659 | NaN | NaN | NaN | TCGA-D8-A1JK-01 | TCGA-D8-A1JK-01 | FEMALE | 90.0 | Negative | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 3.58 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
660 | TNBC | TNBC | TNBC | TCGA-D8-A1JL-01 | TCGA-D8-A1JL-01 | FEMALE | 72.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 8.71 | NaN | NaN | NaN | 2.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
661 | ER+ | ER+ | ER+ | TCGA-D8-A1JM-01 | TCGA-D8-A1JM-01 | FEMALE | 59.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 7.82 | NaN | NaN | NaN | NaN | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
662 | ER+ | ER+ | ER+ | TCGA-D8-A1JN-01 | TCGA-D8-A1JN-01 | FEMALE | 80.0 | Positive | Positive | Negative | T3 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 7.13 | NaN | NaN | NaN | 3.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
663 | ER+ | ER+ | ER+ | TCGA-D8-A1JP-01 | TCGA-D8-A1JP-01 | FEMALE | 73.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 5.49 | NaN | NaN | NaN | 6.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
664 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A1X5-01 | TCGA-D8-A1X5-01 | FEMALE | 81.0 | Positive | Positive | Positive | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 5.62 | NaN | NaN | NaN | 5.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
665 | ER+ | ER+ | ER+ | TCGA-D8-A1X6-01 | TCGA-D8-A1X6-01 | FEMALE | 80.0 | Positive | Positive | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 7.75 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
666 | ER+ | ER+ | ER+ | TCGA-D8-A1X7-01 | TCGA-D8-A1X7-01 | FEMALE | 40.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 2.79 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
667 | ER+ | ER+ | ER+ | TCGA-D8-A1X8-01 | TCGA-D8-A1X8-01 | FEMALE | 62.0 | Positive | Indeterminate | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIA | Stage IIIA | enrollment | LIVING | 8.94 | NaN | NaN | NaN | 1.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
668 | ER+ | ER+ | ER+ | TCGA-D8-A1X9-01 | TCGA-D8-A1X9-01 | FEMALE | 66.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | Stage IIB | enrollment | LIVING | 12.48 | NaN | NaN | NaN | NaN | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
669 | ER+ | ER+ | ER+ | TCGA-D8-A1XA-01 | TCGA-D8-A1XA-01 | FEMALE | 64.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 9.00 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
670 | ER+ | ER+ | ER+ | TCGA-D8-A1XB-01 | TCGA-D8-A1XB-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 6.60 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
671 | ER+ | ER+ | ER+ | TCGA-D8-A1XC-01 | TCGA-D8-A1XC-01 | FEMALE | 85.0 | Positive | Positive | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 2.66 | NaN | NaN | NaN | 7.0 | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
672 | ER+ | ER+ | ER+ | TCGA-D8-A1XD-01 | TCGA-D8-A1XD-01 | FEMALE | 36.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 5.09 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
673 | ER+ | ER+ | ER+ | TCGA-D8-A1XF-01 | TCGA-D8-A1XF-01 | FEMALE | 45.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 6.47 | NaN | NaN | NaN | 5.0 | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
674 | ER+ | ER+ | ER+ | TCGA-D8-A1XG-01 | TCGA-D8-A1XG-01 | FEMALE | 86.0 | Positive | Negative | Negative | T4 | T_Other | N1 | Positive | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 6.44 | NaN | NaN | NaN | 1.0 | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
675 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A1XJ-01 | TCGA-D8-A1XJ-01 | FEMALE | 76.0 | Positive | Positive | Positive | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 11.56 | NaN | NaN | NaN | 7.0 | 3.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
676 | TNBC | TNBC | TNBC | TCGA-D8-A1XK-01 | TCGA-D8-A1XK-01 | FEMALE | 55.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IB | Stage IIB | enrollment | LIVING | 10.71 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
677 | ER+ | ER+ | ER+ | TCGA-D8-A1XL-01 | TCGA-D8-A1XL-01 | FEMALE | 34.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 10.48 | NaN | NaN | NaN | 7.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
678 | ER+ | ER+ | ER+ | TCGA-D8-A1XM-01 | TCGA-D8-A1XM-01 | FEMALE | 57.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 7.16 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
679 | TNBC | TNBC | TNBC | TCGA-D8-A1XQ-01 | TCGA-D8-A1XQ-01 | FEMALE | 69.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 5.82 | NaN | NaN | NaN | 3.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
680 | ER+ | ER+ | ER+ | TCGA-D8-A1XR-01 | TCGA-D8-A1XR-01 | FEMALE | 56.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 5.52 | NaN | NaN | NaN | 3.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
681 | ER+ | ER+ | ER+ | TCGA-D8-A1XU-01 | TCGA-D8-A1XU-01 | FEMALE | 56.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 4.90 | NaN | NaN | NaN | 6.0 | 3.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
682 | ER+ | ER+ | ER+ | TCGA-D8-A1XV-01 | TCGA-D8-A1XV-01 | FEMALE | 84.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 4.80 | NaN | NaN | NaN | 7.0 | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
683 | NaN | NaN | NaN | TCGA-D8-A1XW-01 | TCGA-D8-A1XW-01 | FEMALE | 53.0 | Negative | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 3.84 | NaN | NaN | NaN | 3.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
684 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A1XY-01 | TCGA-D8-A1XY-01 | FEMALE | 74.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 2.66 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
685 | ER+ | ER+ | ER+ | TCGA-D8-A1XZ-01 | TCGA-D8-A1XZ-01 | FEMALE | 81.0 | Positive | Negative | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 3.94 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
686 | ER+ | ER+ | ER+ | TCGA-D8-A1Y0-01 | TCGA-D8-A1Y0-01 | FEMALE | 65.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 5.45 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
687 | ER+ | ER+ | ER+ | TCGA-D8-A1Y1-01 | TCGA-D8-A1Y1-01 | FEMALE | 80.0 | Positive | Positive | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 3.78 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
688 | ER+ | ER+ | ER+ | TCGA-D8-A1Y2-01 | TCGA-D8-A1Y2-01 | FEMALE | 71.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 2.37 | NaN | NaN | NaN | NaN | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
689 | ER+ | ER+ | ER+ | TCGA-D8-A1Y3-01 | TCGA-D8-A1Y3-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 4.07 | NaN | NaN | NaN | NaN | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
690 | ER+ | ER+ | ER+ | TCGA-D8-A27E-01 | TCGA-D8-A27E-01 | FEMALE | 66.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 5.98 | NaN | NaN | NaN | NaN | 5.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
691 | TNBC | TNBC | TNBC | TCGA-D8-A27F-01 | TCGA-D8-A27F-01 | FEMALE | 40.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 7.46 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
692 | ER+ | ER+ | ER+ | TCGA-D8-A27G-01 | TCGA-D8-A27G-01 | FEMALE | 75.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 6.87 | NaN | NaN | NaN | NaN | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
693 | TNBC | TNBC | TNBC | TCGA-D8-A27H-01 | TCGA-D8-A27H-01 | FEMALE | 72.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 4.60 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
694 | ER+ | ER+ | ER+ | TCGA-D8-A27I-01 | TCGA-D8-A27I-01 | FEMALE | 58.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 6.08 | NaN | NaN | NaN | NaN | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
695 | ER+ | ER+ | ER+ | TCGA-D8-A27K-01 | TCGA-D8-A27K-01 | FEMALE | 47.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 3.88 | NaN | NaN | NaN | NaN | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
696 | ER+ | ER+ | ER+ | TCGA-D8-A27L-01 | TCGA-D8-A27L-01 | FEMALE | 49.0 | Positive | Positive | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIB | Stage IIIA | enrollment | LIVING | 4.11 | NaN | NaN | NaN | NaN | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
697 | TNBC | TNBC | TNBC | TCGA-D8-A27M-01 | TCGA-D8-A27M-01 | FEMALE | 59.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IIA | Stage I | enrollment | LIVING | 4.73 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
698 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A27N-01 | TCGA-D8-A27N-01 | FEMALE | 36.0 | Positive | Positive | Positive | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 4.76 | NaN | NaN | NaN | NaN | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
699 | ER+ | ER+ | ER+ | TCGA-D8-A27P-01 | TCGA-D8-A27P-01 | FEMALE | 64.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IIA | Stage I | enrollment | LIVING | 0.72 | NaN | NaN | NaN | NaN | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
700 | ER+ | ER+ | ER+ | TCGA-D8-A27R-01 | TCGA-D8-A27R-01 | FEMALE | 41.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 2.96 | NaN | NaN | NaN | NaN | 1.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
701 | ER+ | ER+ | ER+ | TCGA-D8-A27T-01 | TCGA-D8-A27T-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 4.44 | NaN | NaN | NaN | NaN | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
702 | ER+ | ER+ | ER+ | TCGA-D8-A27V-01 | TCGA-D8-A27V-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 2.40 | NaN | NaN | NaN | NaN | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
703 | HER2+ | ER+ | ER+/HER2+ | TCGA-D8-A27W-01 | TCGA-D8-A27W-01 | FEMALE | 55.0 | Positive | Positive | Positive | T4 | T_Other | N0 | Negative | M0 | Negative | Stage IIIB | Stage IIIB | enrollment | LIVING | 0.49 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
704 | ER+ | ER+ | ER+ | TCGA-E2-A1IE-01 | TCGA-E2-A1IE-01 | FEMALE | 61.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 32.30 | NaN | NaN | NaN | 6.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
705 | ER+ | ER+ | ER+ | TCGA-E2-A1IF-01 | TCGA-E2-A1IF-01 | FEMALE | 74.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 31.41 | NaN | NaN | NaN | 6.0 | 5.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
706 | ER+ | ER+ | ER+ | TCGA-E2-A1IG-01 | TCGA-E2-A1IG-01 | FEMALE | 45.0 | Positive | Positive | Not Available | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 24.81 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
707 | ER+ | ER+ | ER+ | TCGA-E2-A1IH-01 | TCGA-E2-A1IH-01 | FEMALE | 80.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 21.62 | NaN | NaN | NaN | 6.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
708 | NaN | NaN | NaN | TCGA-E2-A1II-01 | TCGA-E2-A1II-01 | FEMALE | 51.0 | Negative | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 27.93 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
709 | ER+ | ER+ | ER+ | TCGA-E2-A1IJ-01 | TCGA-E2-A1IJ-01 | FEMALE | 57.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 23.82 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
710 | ER+ | ER+ | ER+ | TCGA-E2-A1IK-01 | TCGA-E2-A1IK-01 | FEMALE | 71.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 17.02 | NaN | NaN | NaN | 7.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
711 | ER+ | ER+ | ER+ | TCGA-E2-A1IL-01 | TCGA-E2-A1IL-01 | FEMALE | 78.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.46 | NaN | NaN | NaN | 6.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
712 | ER+ | ER+ | ER+ | TCGA-E2-A1IN-01 | TCGA-E2-A1IN-01 | FEMALE | 60.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 12.88 | NaN | NaN | NaN | 2.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
713 | ER+ | ER+ | ER+ | TCGA-E2-A1IO-01 | TCGA-E2-A1IO-01 | FEMALE | 37.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 14.72 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
714 | ER+ | ER+ | ER+ | TCGA-E2-A1IP-01 | TCGA-E2-A1IP-01 | FEMALE | 42.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 14.03 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
715 | ER+ | ER+ | ER+ | TCGA-E2-A1IU-01 | TCGA-E2-A1IU-01 | FEMALE | 60.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 4.17 | NaN | NaN | NaN | 2.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
716 | ER+ | ER+ | ER+ | TCGA-E2-A1L6-01 | TCGA-E2-A1L6-01 | FEMALE | 44.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 43.11 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
717 | TNBC | TNBC | TNBC | TCGA-E2-A1L7-01 | TCGA-E2-A1L7-01 | FEMALE | 40.0 | Negative | Negative | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 20.80 | NaN | NaN | NaN | 5.0 | 2.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
718 | ER+ | ER+ | ER+ | TCGA-E2-A1L8-01 | TCGA-E2-A1L8-01 | FEMALE | 52.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIA | Stage IIB | enrollment | LIVING | 33.35 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
719 | ER+ | ER+ | ER+ | TCGA-E2-A1L9-01 | TCGA-E2-A1L9-01 | FEMALE | 40.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIB | Stage IIA | enrollment | LIVING | 12.75 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
720 | ER+ | ER+ | ER+ | TCGA-E2-A1LA-01 | TCGA-E2-A1LA-01 | FEMALE | 59.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 15.21 | NaN | NaN | NaN | 2.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
721 | HER2+ | HER2+ | ER-/HER2+ | TCGA-E2-A1LB-01 | TCGA-E2-A1LB-01 | FEMALE | 41.0 | Negative | Negative | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 31.94 | NaN | NaN | NaN | 3.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
722 | TNBC | TNBC | TNBC | TCGA-E2-A1LG-01 | TCGA-E2-A1LG-01 | FEMALE | 50.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 11.50 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
723 | TNBC | TNBC | TNBC | TCGA-E2-A1LH-01 | TCGA-E2-A1LH-01 | FEMALE | 59.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 94.46 | NaN | NaN | NaN | NaN | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
724 | TNBC | TNBC | TNBC | TCGA-E2-A1LI-01 | TCGA-E2-A1LI-01 | FEMALE | 57.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 90.35 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
725 | TNBC | TNBC | TNBC | TCGA-E2-A1LL-01 | TCGA-E2-A1LL-01 | FEMALE | 73.0 | Negative | Negative | Negative | T3 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 33.31 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
726 | TNBC | TNBC | TNBC | TCGA-E2-A1LS-01 | TCGA-E2-A1LS-01 | FEMALE | 46.0 | Negative | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 7.85 | NaN | NaN | NaN | NaN | 3.0 | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
727 | NaN | NaN | NaN | TCGA-E9-A1N3-01 | TCGA-E9-A1N3-01 | FEMALE | 70.0 | Not Performed | Not Performed | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
728 | ER+ | ER+ | ER+ | TCGA-E9-A1N4-01 | TCGA-E9-A1N4-01 | FEMALE | 41.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 7.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
729 | ER+ | ER+ | ER+ | TCGA-E9-A1N5-01 | TCGA-E9-A1N5-01 | FEMALE | 45.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
730 | HER2+ | ER+ | ER+/HER2+ | TCGA-E9-A1N6-01 | TCGA-E9-A1N6-01 | FEMALE | 52.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
731 | NaN | NaN | NaN | TCGA-E9-A1N8-01 | TCGA-E9-A1N8-01 | FEMALE | 48.0 | Negative | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
732 | NaN | NaN | NaN | TCGA-E9-A1N9-01 | TCGA-E9-A1N9-01 | FEMALE | 58.0 | Negative | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 5.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
733 | ER+ | ER+ | ER+ | TCGA-E9-A1NA-01 | TCGA-E9-A1NA-01 | FEMALE | 58.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
734 | NaN | NaN | NaN | TCGA-E9-A1NC-01 | TCGA-E9-A1NC-01 | FEMALE | 61.0 | Negative | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
735 | TNBC | TNBC | TNBC | TCGA-E9-A1ND-01 | TCGA-E9-A1ND-01 | FEMALE | 75.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
736 | ER+ | ER+ | ER+ | TCGA-E9-A1NE-01 | TCGA-E9-A1NE-01 | FEMALE | 28.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 6.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
737 | ER+ | ER+ | ER+ | TCGA-E9-A1NF-01 | TCGA-E9-A1NF-01 | FEMALE | 60.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
738 | ER+ | ER+ | ER+ | TCGA-E9-A1NG-01 | TCGA-E9-A1NG-01 | FEMALE | 62.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
739 | ER+ | ER+ | ER+ | TCGA-E9-A1NH-01 | TCGA-E9-A1NH-01 | FEMALE | 71.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
740 | ER+ | ER+ | ER+ | TCGA-E9-A1NI-01 | TCGA-E9-A1NI-01 | FEMALE | 51.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
741 | NaN | NaN | NaN | TCGA-E9-A1QZ-01 | TCGA-E9-A1QZ-01 | FEMALE | 61.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
742 | NaN | NaN | NaN | TCGA-E9-A1R0-01 | TCGA-E9-A1R0-01 | FEMALE | 58.0 | Not Performed | Not Performed | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
743 | ER+ | ER+ | ER+ | TCGA-E9-A1R2-01 | TCGA-E9-A1R2-01 | FEMALE | 51.0 | Positive | Negative | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 0.62 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
744 | NaN | NaN | NaN | TCGA-E9-A1R3-01 | TCGA-E9-A1R3-01 | FEMALE | 70.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 2.10 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
745 | NaN | NaN | NaN | TCGA-E9-A1R4-01 | TCGA-E9-A1R4-01 | FEMALE | 66.0 | Not Performed | Not Performed | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 0.95 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
746 | NaN | NaN | NaN | TCGA-E9-A1R5-01 | TCGA-E9-A1R5-01 | FEMALE | 63.0 | Not Performed | Not Performed | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 1.38 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
747 | NaN | NaN | NaN | TCGA-E9-A1R6-01 | TCGA-E9-A1R6-01 | FEMALE | 63.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 2.76 | NaN | NaN | NaN | 2.0 | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
748 | NaN | NaN | NaN | TCGA-E9-A1R7-01 | TCGA-E9-A1R7-01 | FEMALE | 64.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 1.12 | NaN | NaN | NaN | 1.0 | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
749 | NaN | NaN | NaN | TCGA-E9-A1RA-01 | TCGA-E9-A1RA-01 | FEMALE | 48.0 | Not Performed | Not Performed | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 0.95 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
750 | NaN | NaN | NaN | TCGA-E9-A1RB-01 | TCGA-E9-A1RB-01 | FEMALE | 40.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.69 | NaN | NaN | NaN | NaN | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
751 | NaN | NaN | NaN | TCGA-E9-A1RC-01 | TCGA-E9-A1RC-01 | FEMALE | 56.0 | Not Performed | Not Performed | Negative | T4 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 40.35 | NaN | NaN | NaN | NaN | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
752 | NaN | NaN | NaN | TCGA-E9-A1RD-01 | TCGA-E9-A1RD-01 | FEMALE | 67.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.66 | NaN | NaN | NaN | NaN | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
753 | NaN | NaN | NaN | TCGA-E9-A1RE-01 | TCGA-E9-A1RE-01 | FEMALE | 74.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 1.54 | NaN | NaN | NaN | NaN | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
754 | NaN | NaN | NaN | TCGA-E9-A1RF-01 | TCGA-E9-A1RF-01 | FEMALE | 68.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 1.25 | NaN | NaN | NaN | NaN | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
755 | NaN | NaN | NaN | TCGA-E9-A1RG-01 | TCGA-E9-A1RG-01 | FEMALE | 62.0 | Not Performed | Not Performed | Negative | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 1.15 | NaN | NaN | NaN | 5.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
756 | NaN | NaN | NaN | TCGA-E9-A1RH-01 | TCGA-E9-A1RH-01 | FEMALE | 63.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.46 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
757 | NaN | NaN | NaN | TCGA-E9-A1RI-01 | TCGA-E9-A1RI-01 | FEMALE | 43.0 | Not Performed | Not Performed | Not Available | T1 | T1 | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 1.58 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
758 | NaN | NaN | NaN | TCGA-E9-A226-01 | TCGA-E9-A226-01 | FEMALE | 45.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.53 | NaN | NaN | NaN | NaN | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
759 | ER+ | ER+ | ER+ | TCGA-E9-A227-01 | TCGA-E9-A227-01 | FEMALE | 42.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.79 | NaN | NaN | NaN | NaN | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
760 | HER2+ | HER2+ | None | TCGA-E9-A228-01 | TCGA-E9-A228-01 | FEMALE | 58.0 | Not Performed | Not Performed | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
761 | NaN | NaN | NaN | TCGA-E9-A229-01 | TCGA-E9-A229-01 | FEMALE | 37.0 | Not Performed | Not Performed | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 1.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
762 | ER+ | ER+ | ER+ | TCGA-E9-A22A-01 | TCGA-E9-A22A-01 | FEMALE | 74.0 | Positive | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 3.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
763 | ER+ | ER+ | ER+ | TCGA-E9-A22B-01 | TCGA-E9-A22B-01 | FEMALE | 71.0 | Positive | Negative | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
764 | HER2+ | ER+ | ER+/HER2+ | TCGA-E9-A22D-01 | TCGA-E9-A22D-01 | FEMALE | 38.0 | Positive | Positive | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 3.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
765 | ER+ | ER+ | ER+ | TCGA-E9-A22E-01 | TCGA-E9-A22E-01 | FEMALE | 56.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
766 | TNBC | TNBC | TNBC | TCGA-E9-A22G-01 | TCGA-E9-A22G-01 | FEMALE | 47.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIIA | Stage IIA | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 3.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
767 | ER+ | ER+ | ER+ | TCGA-E9-A22H-01 | TCGA-E9-A22H-01 | FEMALE | 42.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.00 | NaN | NaN | NaN | NaN | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
768 | NaN | NaN | NaN | TCGA-E9-A243-01 | TCGA-E9-A243-01 | FEMALE | 52.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 1.41 | NaN | NaN | NaN | 3.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
769 | NaN | NaN | NaN | TCGA-E9-A244-01 | TCGA-E9-A244-01 | FEMALE | 54.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.66 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
770 | NaN | NaN | NaN | TCGA-E9-A245-01 | TCGA-E9-A245-01 | FEMALE | 47.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 0.82 | NaN | NaN | NaN | NaN | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
771 | NaN | NaN | NaN | TCGA-E9-A247-01 | TCGA-E9-A247-01 | FEMALE | 59.0 | Not Performed | Not Performed | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IB | Stage I | enrollment | LIVING | 0.39 | NaN | NaN | NaN | NaN | 3.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
772 | NaN | NaN | NaN | TCGA-E9-A248-01 | TCGA-E9-A248-01 | FEMALE | 51.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.69 | NaN | NaN | NaN | 3.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
773 | NaN | NaN | NaN | TCGA-E9-A249-01 | TCGA-E9-A249-01 | FEMALE | 45.0 | Not Performed | Not Performed | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.92 | NaN | NaN | NaN | 3.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
774 | NaN | NaN | NaN | TCGA-E9-A24A-01 | TCGA-E9-A24A-01 | FEMALE | 69.0 | Not Performed | Not Performed | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 0.33 | NaN | NaN | NaN | 2.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
775 | HER2+ | ER+ | ER+/HER2+ | TCGA-EW-A1IW-01 | TCGA-EW-A1IW-01 | FEMALE | 80.0 | Positive | Positive | Positive | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 8.28 | NaN | NaN | NaN | 4.0 | 3.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
776 | ER+ | ER+ | ER+ | TCGA-EW-A1IX-01 | TCGA-EW-A1IX-01 | FEMALE | 48.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 35.55 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
777 | ER+ | ER+ | ER+ | TCGA-EW-A1IY-01 | TCGA-EW-A1IY-01 | FEMALE | 38.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 8.48 | NaN | NaN | NaN | 7.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
778 | ER+ | ER+ | ER+ | TCGA-EW-A1IZ-01 | TCGA-EW-A1IZ-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N2 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 8.54 | NaN | NaN | NaN | 3.0 | 2.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
779 | ER+ | ER+ | ER+ | TCGA-EW-A1J1-01 | TCGA-EW-A1J1-01 | FEMALE | 38.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 9.27 | NaN | NaN | NaN | 5.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
780 | ER+ | ER+ | ER+ | TCGA-EW-A1J2-01 | TCGA-EW-A1J2-01 | FEMALE | 50.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIB | Stage IIA | enrollment | LIVING | 4.57 | NaN | NaN | NaN | 6.0 | 2.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
781 | HER2+ | ER+ | ER+/HER2+ | TCGA-EW-A1J3-01 | TCGA-EW-A1J3-01 | FEMALE | 61.0 | Positive | Positive | Positive | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 8.28 | NaN | NaN | NaN | 2.0 | 4.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
782 | ER+ | ER+ | ER+ | TCGA-EW-A1J5-01 | TCGA-EW-A1J5-01 | FEMALE | 59.0 | Positive | Positive | Negative | T3 | T_Other | N0 | Negative | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 7.46 | NaN | NaN | NaN | 7.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
783 | ER+ | ER+ | ER+ | TCGA-EW-A1J6-01 | TCGA-EW-A1J6-01 | FEMALE | 70.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage I | Stage I | enrollment | LIVING | 19.55 | NaN | NaN | NaN | 2.0 | 5.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
784 | TNBC | TNBC | TNBC | TCGA-EW-A1OV-01 | TCGA-EW-A1OV-01 | FEMALE | 56.0 | Negative | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 17.15 | NaN | NaN | NaN | 5.0 | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
785 | TNBC | TNBC | TNBC | TCGA-EW-A1OW-01 | TCGA-EW-A1OW-01 | FEMALE | 58.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 15.21 | NaN | NaN | NaN | NaN | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
786 | ER+ | ER+ | ER+ | TCGA-EW-A1OX-01 | TCGA-EW-A1OX-01 | FEMALE | 43.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 18.46 | NaN | NaN | NaN | 1.0 | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
787 | ER+ | ER+ | ER+ | TCGA-EW-A1OY-01 | TCGA-EW-A1OY-01 | FEMALE | 63.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 19.48 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
788 | HER2+ | ER+ | ER+/HER2+ | TCGA-EW-A1OZ-01 | TCGA-EW-A1OZ-01 | FEMALE | 56.0 | Positive | Negative | Positive | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 30.92 | NaN | NaN | NaN | 4.0 | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
789 | ER+ | ER+ | ER+ | TCGA-EW-A1P0-01 | TCGA-EW-A1P0-01 | FEMALE | 55.0 | Positive | Negative | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 36.83 | NaN | NaN | NaN | 7.0 | 5.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
790 | TNBC | TNBC | TNBC | TCGA-EW-A1P1-01 | TCGA-EW-A1P1-01 | FEMALE | 68.0 | Negative | Negative | Negative | T2 | T_Other | N3 | Positive | M0 | Negative | Stage IIIC | Stage IIIC | enrollment | LIVING | 30.19 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
791 | ER+ | ER+ | ER+ | TCGA-EW-A1P3-01 | TCGA-EW-A1P3-01 | FEMALE | 48.0 | Positive | Positive | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 32.43 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
792 | TNBC | TNBC | TNBC | TCGA-EW-A1P4-01 | TCGA-EW-A1P4-01 | FEMALE | 43.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 16.46 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
793 | ER+ | ER+ | ER+ | TCGA-EW-A1P5-01 | TCGA-EW-A1P5-01 | FEMALE | 77.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 11.99 | NaN | NaN | NaN | 3.0 | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
794 | ER+ | ER+ | ER+ | TCGA-EW-A1P6-01 | TCGA-EW-A1P6-01 | FEMALE | 64.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 10.25 | NaN | NaN | NaN | 2.0 | 2.0 | NaN | 4.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
795 | TNBC | TNBC | TNBC | TCGA-EW-A1P7-01 | TCGA-EW-A1P7-01 | FEMALE | 59.0 | Negative | Negative | Negative | T2 | T_Other | N0 | Negative | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 20.86 | NaN | NaN | NaN | 3.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
796 | ER+ | ER+ | ER+ | TCGA-EW-A1PA-01 | TCGA-EW-A1PA-01 | FEMALE | 59.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 8.77 | NaN | NaN | NaN | NaN | 4.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
797 | TNBC | TNBC | TNBC | TCGA-EW-A1PB-01 | TCGA-EW-A1PB-01 | FEMALE | 70.0 | Negative | Negative | Negative | T3 | T_Other | N1 | Positive | M0 | Negative | Stage IIIA | Stage IIIA | enrollment | LIVING | 19.98 | NaN | NaN | NaN | 2.0 | 5.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
798 | HER2+ | ER+ | ER+/HER2+ | TCGA-EW-A1PD-01 | TCGA-EW-A1PD-01 | MALE | 61.0 | Positive | Positive | Positive | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 5.72 | NaN | NaN | NaN | 4.0 | 2.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
799 | ER+ | ER+ | ER+ | TCGA-EW-A1PE-01 | TCGA-EW-A1PE-01 | FEMALE | 56.0 | Positive | Positive | Negative | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 4.57 | NaN | NaN | NaN | 3.0 | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
800 | ER+ | ER+ | ER+ | TCGA-EW-A1PF-01 | TCGA-EW-A1PF-01 | FEMALE | 50.0 | Positive | Positive | Negative | T1 | T1 | N0 | Negative | M0 | Negative | Stage IA | Stage I | enrollment | LIVING | 4.57 | NaN | NaN | NaN | 4.0 | 1.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
801 | ER+ | ER+ | ER+ | TCGA-EW-A1PG-01 | TCGA-EW-A1PG-01 | FEMALE | 53.0 | Positive | Positive | Negative | T2 | T_Other | N1 | Positive | M0 | Negative | Stage IIB | Stage IIB | enrollment | LIVING | 28.75 | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
802 | NaN | NaN | NaN | TCGA-EW-A1PH-01 | TCGA-EW-A1PH-01 | FEMALE | 52.0 | Negative | Negative | Not Available | T1 | T1 | N1 | Positive | M0 | Negative | Stage IIA | Stage IIA | enrollment | LIVING | 4.57 | NaN | NaN | NaN | 5.0 | 5.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
803 | ER+ | ER+ | ER+ | TCGA-EW-A2FS-01 | TCGA-EW-A2FS-01 | FEMALE | 41.0 | Positive | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 38.54 | NaN | NaN | NaN | NaN | 4.0 | NaN | 5.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
804 | ER+ | ER+ | ER+ | TCGA-EW-A2FV-01 | TCGA-EW-A2FV-01 | FEMALE | 39.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 7.82 | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
805 | ER+ | ER+ | ER+ | TCGA-EW-A2FW-01 | TCGA-EW-A2FW-01 | FEMALE | 52.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 6.24 | NaN | NaN | NaN | NaN | 2.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
806 | ER+ | ER+ | ER+ | TCGA-GM-A2DA-01 | TCGA-GM-A2DA-01 | FEMALE | 46.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 194.14 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
807 | NaN | NaN | NaN | TCGA-GM-A2DB-01 | TCGA-GM-A2DB-01 | FEMALE | 62.0 | Negative | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 53.06 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
808 | ER+ | ER+ | ER+ | TCGA-GM-A2DC-01 | TCGA-GM-A2DC-01 | FEMALE | 57.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 53.49 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
809 | NaN | NaN | NaN | TCGA-GM-A2DD-01 | TCGA-GM-A2DD-01 | FEMALE | 53.0 | Negative | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 43.01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
810 | NaN | NaN | NaN | TCGA-GM-A2DF-01 | TCGA-GM-A2DF-01 | FEMALE | 53.0 | Negative | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 42.68 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
811 | NaN | NaN | NaN | TCGA-GM-A2DH-01 | TCGA-GM-A2DH-01 | FEMALE | 58.0 | Negative | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 42.25 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
812 | NaN | NaN | NaN | TCGA-GM-A2DI-01 | TCGA-GM-A2DI-01 | FEMALE | 52.0 | Negative | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 61.87 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
813 | ER+ | ER+ | ER+ | TCGA-GM-A2DK-01 | TCGA-GM-A2DK-01 | FEMALE | 58.0 | Positive | Negative | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 62.29 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
814 | ER+ | ER+ | ER+ | TCGA-GM-A2DL-01 | TCGA-GM-A2DL-01 | FEMALE | 50.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 90.75 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
815 | ER+ | ER+ | ER+ | TCGA-GM-A2DM-01 | TCGA-GM-A2DM-01 | FEMALE | 57.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 76.58 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
816 | ER+ | ER+ | ER+ | TCGA-GM-A2DN-01 | TCGA-GM-A2DN-01 | FEMALE | 58.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 77.27 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
817 | ER+ | ER+ | ER+ | TCGA-GM-A2DO-01 | TCGA-GM-A2DO-01 | FEMALE | 54.0 | Positive | Positive | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | enrollment | LIVING | 53.29 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
818 | NaN | NaN | NaN | TCGA-AR-A24W-01 | TCGA-AR-A24W-01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 6.0 | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
819 | NaN | NaN | NaN | TCGA-AC-A2B8-01 | TCGA-AC-A2B8-01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
820 | NaN | NaN | NaN | TCGA-AC-A2FF-01 | TCGA-AC-A2FF-01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 1.0 | NaN | 1.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
821 | NaN | NaN | NaN | TCGA-AC-A2FB-01 | TCGA-AC-A2FB-01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 1.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
822 | NaN | NaN | NaN | TCGA-AC-A2FG-01 | TCGA-AC-A2FG-01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 1.0 | NaN | 2.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
823 | NaN | NaN | NaN | TCGA-GI-A2C8-01 | TCGA-GI-A2C8-01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 3.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |
824 | NaN | NaN | NaN | TCGA-E9-A295-01 | TCGA-E9-A295-01 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 4.0 | NaN | 3.0 | NaN | NaN | NaN | Breast Cancer | Invasive Breast Carcinoma |